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 The causative agents of most diseases like cancer and Alzheimer’s are proteins. 
The function of a protein can be fully appreciated only when we have a complete 
knowledge of its 3-dimensional structure, as structure and function go hand in hand. 
Decades of effort using X-ray crystallography and NMR have produced thousands of 
protein and complex with binding partner structures and these structures provide a rich 
source of data for learning the principles of how proteins interact and for rational design 
and engineering of therapeutics. Here, we are particularly keen on figuring out how 
proteins are involved in gene regulation under stress by interacting with their partners and 
the use of a rational approach for protein design and engineering to change the substrate 
specificity of a protease inhibitor. 
 This PhD thesis consists of five chapters. Chapter I deals with the literature 
survey and general introduction about the thioredoxin (Trx) system (an antioxidant) and 
briefly covers the various strategies of structure based protein design and engineering to 
develop drugs against a specific protease inhibitor. Chapter II deals with the structural 
and functional characterization of thioredoxin like protein 16 from Carcinoscorpius 
rotundicauda (Cr-TRP16), a 16 kDa Trx-like protein that contains a WCPPC motif. We 
present the NMR structure of the reduced form of Cr-TRP16, along with its regulation of 
NF-κB activity. Unlike other 16 kDa Trx-like proteins, Cr-TRP16 contains an additional 
Cys residue (Cys15, at the N-terminus), through which it forms a homo-dimer. Moreover 
we have explored the molecular basis of Cr-TRP16 mediated activation of NF-κB in the 
HeLa cell and show that Cr-TRP16 exists as a dimer under an oxidized condition and 
only the dimeric form binds to NF-κB and enhances its DNA-binding activity by directly 
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reducing the cysteines in the DNA-binding motif of NF-κB. The C15S mutant of Cr-
TRP16 is unable to dimerize and hence does not bind to NF-κB.  
 Based on our finding and combined with the literature, we propose a model on 
how Cr-TRP16 is likely to bind to NF-κB. These findings elucidate the molecular 
mechanism by which NF-κB activation is regulated by Cr-TRP16. Chapter III reports the 
expression and purification of human thioredoxin like protein-6 (TXNL-6), a homolog of 
Cr-TRP16 and protects retinal cells from apoptosis under stress and characterization of its 
interaction with NF-kB.  
 Chapter IV presents the structure based rational design of altered specificity of a 
protease inhibitor. Protease inhibitors play a decisive role in maintaining homeostasis and 
eliciting antimicrobial activities. Invertebrates like horseshoe crab have developed unique 
modalities with serine protease inhibitors to detect and respond to microbial and host 
proteases. Two isoforms of immunomodulatory two-domain Kazal-like serine protease 
inhibitors, CrSPI-1 and CrSPI-2, have been recently identified in the hepatopancreas of 
the horseshoe crab, Carcinoscorpius rotundicauda. Full length and domain 2 of CrSPI-1 
display powerful inhibitory activities against subtilisin. However the structure and 
function of CrSPI-1 domain-1 remain unknown. Here, we report the crystal structure of 
CrSPI-1-D1, refined at 2.0 Å resolution. Despite the close structural homology of CrSPI-
1-D1 to rhodniin-D1 (a known thrombin inhibitor), CrSPI-1-D1 does not inhibit 
thrombin. This prompted us to modify the selectivity of CrSPI-1-D1, specifically towards 
thrombin. Here, we illustrate the use of the structural information of CrSPI-1-D1 to 
modify this domain into a potent thrombin inhibitor with IC50 of 26.3 nM. In addition, 
these studies demonstrate that besides the rigid conformation of the reactive site loop of 
 x 
 
the inhibitor, the sequence is the most important determinant of the specificity of the 
inhibitor. This study will lead to significant applications to modify a multi-domain 
inhibitor protein to target several proteases. Chapter V provides the overall conclusion 
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CHAPTER-I: GENERAL INTRODUCTION 
 
esearch in its highest expression, 
is an open-minded expression inquiry; for truth, 
to be found and revealed unreservedly, 
for the information, instruction, advantage and welfare of ALL” 
        …… Williams J Gies 
 
 Aerobic life depends upon controlled combustion for energy supply. Controlled 
combustion is catalyzed and regulated by metabolic machinery that can be damaged by 
uncontrolled oxidative reactions that are associated with energy production. Due to the 
extreme threat of such uncontrolled oxidation, aerobic life evolved a complex set of 
antioxidant systems to control these reactions and repair or replace the damaged 
machinery. At the same time, enzyme systems evolved to produce reactive species for 
biological signaling, biosynthetic reactions, chemical defense, and detoxification 
functions. The presence of both toxic and beneficial consequences of reactive species 
precludes a simple definition of oxidative stress. 
  The following sections will present a general introduction about the thioredoxin 
system (an antioxidant) in the first part, while the second part briefly covers the various 
strategies of structure based protein design and engineering to develop drugs against 





1.1  REACTIVE OXYGEN SPECIES (ROS) 
 Reactive oxygen species (ROS) is a collective term that describes the chemical 
species that are formed upon incomplete reduction of oxygen and includes the superoxide 
anion (O2–), hydrogen peroxide (H2O2) and the hydroxyl radical (HO). ROS are thought to 
mediate the toxicity of oxygen because of their greater chemical reactivity with regard to 
oxygen. Reactive oxygen species are highly reactive due to the presence of unpaired 
valence shell electrons. ROS are formed as a natural byproduct of the normal metabolism 
of oxygen and have important roles in cell signaling and homeostasis (Flohé et al., 1997; 
Novo and Parola, 2008; Quinn et al., 2002). Fig. 1.1 illustrates the mechanisms for the 
generation of ROS in living cells. 
At the cellular level, ROS may act as second messengers in various signal 
transduction and elicit a wide spectrum of responses ranging from proliferation to growth 
or differentiation arrest, to senescence, to cell death by activating numerous major 
signaling pathways including phosphoinositide 3-kinase (PI-3K), NF-κB, phospholipase 
C-γ1 (PLC- γ1), p53, CREB, HSF and mitogen-activated protein kinases [MAPKs, which 
may classify into: extracellular signal-regulated kinases (ERKs), c-Jun N-terminal (JNK), 
p38 MAPK]. The magnitude and duration of the stress, as well as the cell type involved, 
are important factors in determining which pathways are activated and the particular 





Figure I.1: Cellular sources of ROS in living cells. Adopted from(Novo 
and Parola, 2008).  
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 The continuous efflux of ROS from endogenous and exogenous sources results in 
continuous and accumulative oxidative damage to cellular components (Comporti, 1989) 
and alters many cellular functions (Gracy et al., 1999). Among the biological targets most 
vulnerable to oxidative damage are proteinaceous enzymes (Davies et al., 1987; Levine 
and Stadtman, 2001), lipidic membranes (Davies et al., 1987), and DNA (Beckman and 
Ames, 1997; Chang et al., 2007) (Fig. 1.2).  
 
 
Figure I.2: Schematic representation of various activators and inhibitors 
of reactive oxygen species production. Adopted from (Reuter et al., 2010). 
  
 Numerous pathologies and disease states serve as sources for the continuous 
production of ROS (Baud and Ardaillou, 1986; Halliwell, 1994; Kawanishi et al., 2002; 
Levy, 1996; Venditti et al., 2002). More than 200 clinical disorders have been described 
in the literature in which ROS were important for the initiation stage of a disease or 
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produced during its course (Table 1.1). ROS may be important initiators and mediators in 
many types of cancer (Brown and Bicknell, 2001; Gracy et al., 1999; Nyska et al., 2002), 
heart diseases, endothelial dysfunction (Aikawa et al., 2001; Farré and Casado, 2001; 
Laroux et al., 2001), atherosclerosis and other cardiovascular disorders, inflammation and 
chronic inflammation (Laroux et al., 2001; Latha and Babu, 2001), burns (Latha and 
Babu, 2001), intestinal tract diseases (Blau et al., 2000), brain degenerative impairments 
(Giasson et al., 2002), diabetes (Opara, 2002), eye diseases (Goldstein et al., 1996), and 
ischemic and post ischemic e.g., damage to skin, heart, brain, kidney, liver, and intestinal 
tract pathologies (Sasaki and Joh, 2007).  
 
Table I.1: A partial list of diseases that have been linked to reactive 
oxygen species. 
Disease  Reference 
Acute respiratory distress syndrome  (Wilson et al., 2001) 
Aging (Dugan and Quick, 2005) 
Acute respiratory distress syndrome (Hensley et al., 1996; Multhaup et al., 
1997) 
Alzheimer  (Nisha and Deshwal, 2011) 
Atherosclerosis  (Lau et al., 2008) 
Cancer (Touyz, 2004)  
Cardiovascular disease (Muhammad et al., 2009) 
Diabetes (Di Virgilio, 2004) 
Inflammation  (Moulton, 1996) 
Inflammatory joint disease  (Bolaños et al., 2009) 
Neurological disease (Atabek et al., 2004) 
Obesity  (Tabner et al., 2001) 
Parkinson (Kamp et al., 1992)  
Pulmonary fibrosis  (Gelderman et al., 2007) 
Rheumatoid arthritis  (Haurani and Pagano, 2007) 
Vascular disease  (Wilson et al., 2001) 
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 In several normal conditions ROS are produced and play a role in the 
pathogenesis of the physiological condition (Fig.1.3). These are exemplified during the 
aging process, where ROS production significantly increases as a result of impaired 
mitochondrial function and in the early stages of embryonic development (Lee and Wei, 
2001). Other pathological disorders, which are associated with impaired metal 
metabolism, such as hemochromatosis (Eaton and Qian, 2002), Wilson disease (Rotilio et 
al., 2000), and thalassemia (Meral et al., 2000), in which iron is deposited in many 
organs, are known to increase significantly the concentration of ROS. 
 
 
Figure I.3: Reactive oxygen species (ROS)-induced oxidative damage. 
Adopted from (Opara, 2002). 
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 Reactive oxygen species (ROS) are known to be mediators of intracellular 
signaling pathways. However the excessive production of ROS may be detrimental to the 
cell as a result of the increased oxidative stress and loss of cell function. Hence, well 
tuned, balanced and responsive antioxidant systems are vital for proper regulation of the 
redox status of the cell. The biological system/cells are normally able to defend 
themselves against the oxidative stress/ROS induced damage by regulating the cellular 
reduction/oxidation (redox) status through the use of several antioxidant systems. Under 
pathologic conditions, the cells develop both enzymatic and non-enzymatic defense 
systems to reduce the concentration of these ROS (Stadtman, 1992).The enzyme 
superoxide dismutase (SOD) deals with the superoxide anions, while the hydrogen 
peroxide so formed from the SOD reaction is detoxified by the catalase (Loshchagin et 
al., 2002) and also by glutathione and thioredoxin dependent peroxidases (Flohé et al., 
1997; Hofmann et al., 2002). The thioredoxin (Trx) system, and the glutathione (GSH) 
system are the two main ubiquitously expressed thiol-reducing antioxidant systems 
(Nordberg and Arnér, 2001). The Trx system (Trx, Trx reductase and NADPH) plays a 




Figure I.4: O2- is converted into H2O2 by superoxide dismutases 
(SODs).H2O2 is then eliminated by catalase, glutathione peroxidases 
(GPxs), and peroxiredoxins (PRxs). During elimination of H2O2, reduced 
glutathione (GSH) is converted to disulfide form (GSSG) by GPxs, and 
then GSSG is recycled to GSH by glutathione reductase (GR). However, 
PRxs also catalyze H2O2 into H2O by using reduced thioredoxin (Trx). 
Oxidized Trx is then recycled back to redTrx by thioredoxin reductase 
(TrxR). NADPH is essential for both recycling reactions. ROS are 
indicated using red characters (Nakano et al., 2005) 
 
1.2  THIOREDOXIN SYSTEM 
The thioredoxin system, comprising with thioredoxin (Trx), thioredoxin reductase 
(TrxR) and NADPH , was discovered by Reichard and coworkers in 1964 as a hydrogen 
donor for the enzymatic synthesis of cytidine deoxyribonucleoside diphosphate by 
ribonucleotide reductase from Escherichia coli (Laurent et al., 1964b) . It is the cells’ 
major protein disulfide reductase, potentially being the physiological equivalent of a 
reducing agent like dithiothreitol (Holmgren, 1989b).  
 
Figure I.5: Redox reactions catalyzed by a mammalian Trx system 
comprising thioredoxin reductase (TrxR), thioredoxin (Trx) and NADPH 
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(Holmgren and Lu, 2010). The electron source of the Trx system is 
NADPH, which is largely produced from the pentose phosphate pathway. 
The oxidized thioredoxin (Trx-S2) is reduced by NADPH and the 
selenoenzyme TrxR. Electrons are transferred from NADPH to FAD, then 
to the N-terminal redox active disulfide in one subunit of TrxR and finally 
to the C-terminal active site Gly–Cys–Sec–Gly of the other subunit (Elias 
S.J, 2009). Reduced thioredoxin [Trx-(SH)2] catalyzes disulfide bond 
reduction in many proteins. Upon oxidative stress, Trx can be secreted 
into plasma or cleaved into Trx80 lacking the C-terminal 20 or 24 amino 
acid residues (Pekkari et al., 2001). 
 
Thioredoxin (Trx), which functions as a general protein-disulfide reductase, is 
commonly known to be a small ubiquitous protein of 12 kDa. It is evolutionarily 
conserved from prokaryotes to eukaryotes, plants, and animals (Holmgren, 1989b). The 
redox activity of Trx has been reported to reside in a conserved active site, Cys-Gly-Pro-
Cys (CGPC), in which the two Cys residues undergo reversible oxidation, converting its 
dithiol group to a disulfide bond (Fig. 1.5) (Powis and Montfort, 2001).  
Trx is maintained in its active reduced form by the thioredoxin reductase (TrxR), 
a selenocysteine-containing protein that uses the reducing power of NADPH (Powis and 
Montfort, 2001). The three-dimensional structure of Trx is conserved throughout 
evolution and consists of four or five central β-strands, surrounded by three or four α-
helices (Fig. 1.6). The active site is located in a protrusion of the protein between the β2-
strand and the α2-helix. Both the conserved active site sequence and the three-






Figure I.6: The three-dimensional structure of E. coli thioredoxin(Kumar 
et al., 2004). The active site redox active disulfide cysteines (C32 and 
C35), shown in yellow, are located in a small cleft in the main body of the 
molecule. 
 
1.2.1 Phylogenetic analysis of Thioredoxin (Trx)  
 Trx was first identified as an electron donor for ribonucleotide reductase for DNA 
synthesis in Escherichia coli (Laurent et al., 1964a).Trx, with a molecular weight of 12 
kDa, is conserved throughout in all prokaryotic and eukaryotic species (Eklund et al., 
1991b). The first characterized human Trx (Trx1) is a 12 kDa protein with a 
catalytic sequence of CGPC. Although bacterial 12 kDa Trx only contains two cysteine 
residues (at its catalytic site), the human 12 kDa Trx contains three other cysteine 
residues. The C-terminal Cys73 is involved in dimerization, and may convey unique 
biological properties to mammalian Trx (Holmgren, 1985).  
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 A second slightly larger Trx-2 is a 166-amino acid protein with a molecular 
weight of 18 kDa, containing a conserved Trx catalytic site. It has been identified in the 
mitochondria of pig’s heart (Spyrou et al, 1997). The 60-amino acid N-terminal extension 
of Trx-2 exhibits characteristics consistent with a mitochondrial translocation signal, and 
the mitochondrial localization of Trx-2 was confirmed by Western blotting (Miranda-
Vizuete et al, 2000). A 32 kDa thioredoxin-like cytosolic protein was first cloned from a 
human testis cDNA library (Lee et al, 1998). The 289 amino acid protein has an N-
terminal Trx domain of 105 amino acids, a conserved Trx active site (CGPC), and a high 
degree of homology to human Trx. It is ubiquitously expressed in the human testis. In 
1997, a type of Trx called nucleoredoxin (NRX) with a WCPPC catalytic site was cloned 
from mice. Interestingly, this 435-amino acid protein is localized to the nucleus (Kurooka 
et al, 1997). Recently, a family of 16 kDa Trx has been identified from the nematodes 
and protozoa of the family Trypanosomatidae with an active site of WCPPC 
(Kunchithapautham et al., 2003). 
 The 14 kDa human Trx (TRP14), with an active motif of WCPDC, exhibits 
markedly different substrate specificity compared to the 12 kDa Trxs. Although TRP14 
could reduce small disulfide-containing peptides, it did not reduce the disulfides of the 
known human Trx1 substrates ribonucleotide reductase and peroxiredoxin (Jeong et al, 
2004b). Although the enzymes of the thioredoxin superfamily do not have a high level of 
sequence similarity, they nevertheless share a marked degree of structural similarity, and 
all having a common sequence CXXC in the active site. 
 The sequence alignment of these homologous proteins reveals that the catalytic 
WCPPC motif is largely conserved, indicating the potential importance of this motif in 
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the Trx function (Fig. 1.7). This highly conserved region is present at the end of an α-
helix in all the enzymes belonging to the super family.  
 
Table I.2: Homology (in percentage*) among thioredoxins from different species 
 
* Only positive matches are scored. No penalties were assigned to gaps or loops. 
Percentages were calculated based on the number of residues (in parentheses) in the 




Figure I.7: Amino acid sequence comparison among thioredoxins from different species. Alignments were 
done by Clustal-X. The active sites are demarcated by a dashed line. This figure was created by using the 




Despite notable differences in the molecular mass and amino acid sequence of the 
catalytic site, those forms of Trxs (Table 1.2) appear to be functionally similar to the 
classical 12 kDa Trxs. Therefore, it appears that there is considerable flexibility in the 
two residues between the conserved Cys residues in the active site, and that the different 
catalytic sequences might confer diverse enzymatic activity and substrate specificity 
(Kunchithapautham et al., 2003). This observation supports the versatility of the Trx 
molecule and reflects its role in anti-oxidative protection of the host. 
 
1.2.2 Biological roles of thioredoxin system 
 Thioredoxins are proteins that act as antioxidants by facilitating the reduction of 
other proteins by cysteine thiol-disulfide exchange (Holmgren, 1989a; Nordberg and 
Arnér, 2001). Trx proteins function as a redox sensor and transducer that impart 
information on the cellular redox status to proteins that do not possess their own redox-
sensitive residues. For instance, the reduced form of Trx1, a mammalian cytosolic 
isoform, binds to and thereby inhibits the activity of apoptosis signal-regulating kinase 1 
(ASK1), an upstream activator of the c-Jun N-terminal kinase (JNK) and p38 mitogen-
activated protein kinase (MAPK) signaling pathways (Liu et al., 2000). Their alterations 
have been implicated in cardiovascular diseases (Aviram, 2000), diabetes (Davi et al., 
2005), hepatic and renal diseases (Seki et al., 2002), Alzheimer's disease (Nunomura et 
al., 2006), Parkinson's disease (Wood-Kaczmar et al., 2006) and rheumatoid arthritis 
(Hitchon and El-Gabalawy, 2004).  
 Some human cancers show greatly increased Trx expression (Fujii et al., 1991; 
Gasdaska et al., 1994), indicating a potential role of Trx in tumorigenesis. Its interactions 
with different proteins of the metabolic and signaling pathways make Trx an attractive 
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target for therapeutic interventions. As illustrated in Fig.1.8, there are numerous systems 
with thiol-dependent redox mechanisms, which are related to important pathological 
states and human diseases.  
 
 
Figure I.8: Biological roles of the thioredoxin system. Adopted from 
(Holmgren and Lu, 2010). 
 
 TrxR1 and Trx1 in cytosol and nucleus, TrxR2 and Trx2 in mitochondria play 
critical roles in biochemical mechanisms. Trx1 reduces ribonucleotide reductase (RNR), 
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which is essential for DNA synthesis. Trx provides the electrons to methionine sulfoxide 
reductase (MSR), and Trx-dependent peroxidases (peroxiredoxins, Prxs) to repair of 
methionine sulfoxide residues in proteins or to protect against oxidative stress via 
removing hydrogen peroxide and peroxynitrite, respectively.  
 The Trx system operates in cellular redox signaling by controlling the activity of 
many transcription factors such as NF-jB, p53, Ref-1, HIFa, PTEN, AP-1, and 
glucocorticoid receptor, and so on (Lillig and Holmgren, 2006). Trx-(SH)2 can bind to 
and inactivate apoptosis signal-regulating kinase (ASK1) and regulate ASK1 dependent 
apoptosis (Saitoh et al., 1998). Thioredoxin interacting protein (TXNIP) binds to Trx-
(SH)2 and regulates Trx activity (Yoshioka et al., 2004). TrxR can reduce protein 
disulfide isomerase (PDI),a critical player for disulfide bond formation (Lillig and 
Holmgren, 2006). Trx-(SH)2 affects the activity of some key proteins, such as caspases, 
via control of protein S-nitrosylation and denitrosylation. 
 The expression of Trx system proteins has been found to be changed in many 
diseases, including cancer, diabetes, cardiovascular and neurodegenerative diseases or 
rheumatoid arthritis (Lillig and Holmgren, 2006). Under the conditions of aging, 
inflammation and virus infection Trx levels are also changed. A Trx-like protein, rod-
derived cone viability factor (TXNL-6) has been shown to be an essential factor to 





1.2.3 Carcinoscorpius rotundicauda thioredoxin related protein 16 
 In addition to Trx, there are several Trx-like proteins, which possess the 
thioredoxin fold and function and exist in different sizes (12-32 kDa). Recently, a 16 kDa 
protein that contains a WCPPC motif has been isolated and characterized from the horse-
shoe crab species Carcinoscorpius rotundicauda, and named as Carcinoscorpius 
rotundicauda Trx-like protein 16 (Cr-TRP16) (Wang et al., 2007). Notably, 16 kDa Trx-
like proteins are functionally similar to the 12 kDa Trxs and contain two Cys residues at 
the active site. Unlike other 16 kDa Trx like proteins, Cr-TRP16 contains an additional 
Cys residue (Cys15, at the N-terminus) but it lacks the extra C-terminal Cys residue (Fig. 
1.9), which is found in mammalian Trxs (Weichsel et al., 1996b).  
 
Figure I.9: Comparison of CXXC motif, numbers and positions of 
cysteine residues in various Trxs.The Cys residues are indicated by dashed 
lines. The sequences of catalytic motif are indicated as well. Adopted from 




Interestingly, like other 16 kDa thioredoxins, Cr-TRP16 also lacks the highly 
conserved Asp26, which is present in the E. coli Trx, and has been shown to play a 
crucial role for catalytic activity. Based on human Trx1 studies, it has been shown that 
mammalian 12 kDa Trxs have three conserved cysteine residues at positions 62, 69 and 
73, besides the two conserved cysteines in the active site motif. Those Cys residues may 
impart unique biological properties to mammalian 12 kDa Trxs (Holmgren, 1989b). 
Furthermore, crystal structure also reveals that human Trx1 can form a dimer via Cys73, 
and the active site residues are buried in the dimer interface (Weichsel et al., 1996a). 
Surprisingly, although most of the 16 kDa Trxs, like the bacterial 12 kDa Trx, do not 
contain an extra Cys residue besides the ones in the active site, Cr-TRP16 possesses an 
extra Cys residue at the N-terminus (Wang et al., 2007).  
Interestingly, while Cr-TRP16 lacks the C-terminal extra Cys residue, it is 
possible it can form a dimer via the N-terminal Cys15. However, at this stage, it is still 
unclear if such dimer also exists under physiological conditions, and therefore, the role of 
the extra N-terminal Cys in dimer formation needs further examination. Further 
mutational and structural studies would be useful to define the function of the extra N-
terminal Cys15 residue in Cr-TRP16. 
 
1.2.4 The influence of Cr-TRP16 in NF-κB signaling pathway 
 For a subtle balance between oxidants and antioxidants which is crucial for 
homeostasis, there is emerging evidence that the highly conserved intracellular redox 
state of Trx regulates signal transduction and gene expression (Sen and Packer, 1996). 
NF-kB is one of the redox-regulated proteins.   
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 It is a member of the Rel family of transcription factors and exists in the 
cytoplasm in complex with its inhibitor protein, IB (Verma, 2004). A wide variety of 
stimuli, including TNF-α, phorbol ester, bacterial lipopolysaccharide, and virus infection, 
can activate NF-B (Menon et al., 1995).  
 NF-B activation involves site-specific phosphorylation of IB-α which results in 
the dissociation of the complex, unmasking of the NF-kB nuclear localization signal and 
nuclear entry of NF-B to bind to its cognate DNA (Zabel and Baeuerle, 1990). Thus, for 
the stimuli that potently and rapidly modulate the nuclear activity of NF-B, the IB-α 
may represent a critical activation target (Verma, 2004). Several studies have suggested 
that Trx is a specifically potent antioxidant for NF-B activation (Schenk et al., 1994). 
Similar to the human Trx1, Cr-TRP16 also up regulates the TNFα-induced NF-κB 
activation.  
  Cr-TRP16 exists as a dimer in the oxidized state. However, the underlying 
mechanism of dimerization and the regulation of NF-κB by Cr-TRP16 are so far 
unknown. For example, what is the physiological role of the Trx-dimer? Is Cys15 
involved in Cr-TRP16 dimer formation? How is NF-κB regulated under oxidized and 
reduced cellular environments? It is possible that the oxidant-induced dimerization 
facilitates sensing cellular oxidative stress. Dimerization might remove Trx from the 
redox cycle, which is catalyzed by TrxR, since the dimer is not a suitable substrate for 
TrxR. In addition, dimerization of secreted Trx in the relatively oxidizing extracellular 
environment could be a way of limiting the growth stimulating effects of Trx (Ren et al., 
1993). Thus, characterization of Trxs and Trx-like proteins from different organisms will 
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enhance the understanding of redox controls, which is another important oxidoreductase 
(Holmgren, 1989b).  
 
Figure I.10: Activation of NF-κB signaling pathway involves 
Trx.Oxidative stress causes activation signals to phosphorylate IκB which 
results in the dissociation of IκB from NF-κB and ubiquitination of IκB. 
Activated NF-κB translocates into the nucleus, and Trx enhances NF-κB 
DNA binding, resulting in the transcription of NF-κB dependent genes. 
Adapted with modification from Alberts et al (2002). 
 
 In order to understand the structure and functional implications of Cr-TRP-16 the 
NMR structure has been determined and subsequent biophysical studies and ex vivo 
studies identified the crucial regulatory role of Cr-TRP16 in NF-kB activity (Fig.1.10). In 
chapter 2 of this thesis these details are reported. In the next part of the general 
introduction chapter, the various strategies for structure based protein design and 




1.3  PROTEIN DESIGN AND ENGINEERING 
Proteins are essential to life and most of them are enzymes, which serve as 
catalysts for nearly all the chemical reactions that define cellular metabolism. Their 
enormous rate accelerations and exact selectivities also make them extremely valuable 
outside the cell. Enzymes are being used increasingly in research, industry and medicine. 
Particularly, protein engineering, an integration of structural biology, chemistry, 
molecular biology and genetics, has much to offer for the modern day chemical and 
pharmaceutical industries. 
Protein engineering is undergoing the most profound and exciting transformation 
in its history(Georgiou and DeWitt, 1999). It promises unprecedented expansion in the 
scope and applications of modified or improved enzymes with desired physical and 
catalytic properties. Two complementary strategies are currently available:  
1. Rational redesign (Chen, 1999; Chen et al., 1995; Chen et al., 1996) and  
2. Directed evolution(Arnold, 1997; Stemmer, 1994).  
 
 Although both approaches have met with great success, each has limitations. 
These techniques are not mutually exclusive (Fig. 1.11). The following section discusses 






Figure I.11: Various strategies for protein design and engineering.Protein 
engineering methods differ widely based on the degree that the enzyme is 
changed and the amount of information available for rational design. 
ProSAR, or protein structure–activity relationship, is described in the text. 
3D, three-dimensional; QM/MM, quantum mechanics or molecular 
mechanics(Kazlauskas and Bornscheuer, 2009). 
 
 
1.3.1 Directed evolution strategies 
 In directed evolution, random mutagenesis is applied to a protein, and a selection 
regime is used to pick out variants that have the desired qualities. Further rounds of 
mutation and selection are then applied. This method mimics natural evolution and 
generally produces superior results to rational design (Nyska et al., 2002; Stemmer, 
1994). An additional technique known as DNA shuffling mixes and matches pieces of 
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successful variants in order to produce better results. This process mimics the 
recombination that occurs naturally during sexual reproduction. The great advantage of 
directed evolution is that it requires no prior structural knowledge of a protein, nor is it 
necessary to be able to predict what effect a given mutation will have.  
 Indeed, the results of directed evolution experiments are often surprising in that 
desired changes are often caused by mutations that were not expected to have that effect. 
The drawback is that they require high-throughput, which is not feasible for all proteins. 
Large amounts of recombinant DNA must be mutated and the products screened for 
desired qualities. The sheer number of variants often requires expensive robotic 
equipment to automate the process. Furthermore, not all desired activities can be easily 
screened for. 
 
1.3.2 Rational redesign strategies 
 Rational design means making an educated guess about which amino acids in an 
enzyme to alter, and then making the changes using targeted, or 'site-directed' 
mutagenesis of the corresponding gene. This approach works best when a high-
resolution, three-dimensional structure of the enzyme has already been obtained using X-
ray crystallography or nuclear magnetic resonance (NMR) spectroscopy. Particularly 
helpful are the structures in which the enzyme is 'caught in the act' with its substrate, a 
substrate-like inhibitor or product. These structures help to identify the residues that are 
at the business centre of the enzyme - its 'active site'. Even in the absence of a structure, it 
is still possible to create a computer model of a protein based upon the structure of the 
enzymes that have similar sequences; a large database that correlates sequences with 
structures is readily available. 
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1.3.3 Rational design and engineering of therapeutic proteins 
 An increasing number of engineered protein therapeutics are currently being 
developed, tested in clinical trials and marketed for use. The controlled manipulation of 
the physical, chemical and biological properties of proteins, enabled by structure-based 
simulation, is now being used to refine established rational engineering approaches and to 
advance new strategies. These methods provide clear, hypothesis driven routes to solve 
problems that plague many proteins and to create novel mechanisms of action. 
 A variety of strategies have emerged for modulating protein properties, such as 
efficacy, stability, specificity, immunogenicity and pharmacokinetics (PK). Mechanisms 
for altering these properties include manipulation of primary structure, incorporation of 
chemical and post-translation modifications and utilization of fusion partners. The most 
common route to optimization is site-directed mutagenesis, which is often performed in a 
brute force or trial-and-error manner. A smaller number of examples exists whereby 
semi-rational application of diversity methods, such as phage display, has been used to 
optimize a therapeutic candidate. Important recent developments are the creation and 
successful application of rational protein design methods and the determination of an 
increasing number of high-resolution protein structures. The controlled modification of 



































Stability ×    × × × 
Solubility ×  × × × × × 
Receptor binding 
affinity and specificity 
 × ×     
MHC binding affinity   × ×    
Oligomerization state  × ×  ×   
Chemical modifications  × × × ×  × 
Posttranslational 
modifications 
 × × ×   × 
Sequence diversity        
Conformational state  ×      
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 An important subset of rational engineering methods consists of the approaches 
that utilize high-resolution, 3D structure information. The most sophisticated of these 
methods offers an extraordinary level of control over protein sequence and structure, a 
mechanism to explore sequence combinations that extends far beyond natural diversity, 
and the ability to couple multiple constraints algorithmically for simultaneous 
optimization of several protein properties. Furthermore, proven hypotheses can be 
reapplied to additional protein systems, thus saving discovery cost and time (Voigt et al., 
2001; Voigt et al., 2002).  
 
Table I.4: Some examples of protein engineering. 
S.N. Example Method Reference 
1 Increased rate and extent of biodesulfurization of 
diesel by modification of dibenzothiophene 
mono-oxygenase 
RACHITT Coco et al. 2001 
2 Generation of a subtilisin with a half-life at 65°C 
that is 50 times greater than wild type by recombining 
segments from five different subtilisin variants 
StEP Zhao et al. 1998 
3 Conversion of a galactosidase into a fucosidase Shuffling Zhang et al. 
1997 
 
4 Enhanced activity of amylosucrase Random 
mutagenesis plus 
shuffling 
Van der Veen et 
al. 2004 
5 Generation of novel DNA polymerases from a 
combination of rat DNA polymerase beta and 
African swine fever virus DNA polymerase X 
SCOPE O’Maille et al. 
2002 
6 Generation of novel β-lactamase by recombining 
two genes with 40% amino acid identity and 49% 
nucleotide sequence identity 
SISDC Hiraga & Arnold 
2003 
Adapted from (Marshall et al., 2003) 
 The exquisite specificity of biological therapeutics for their clinical targets has led 
to their continued development and application as medicines, despite competition from 
small molecule drugs. Several engineered protein therapeutics are currently being 
marketed (Table 1.4 and 1.5), and the annual sales of protein therapeutics are projected to 
exceed US$59 billion in 2010, which is twice the revenue generated in 2001 
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(http://www.pharmafile.com/Pharmafocus/ Features/feature.asp?fID=281). For well-
validated targets, naturally occurring protein interaction partners constitute preselected 
‘lead’ compounds with high affinity and specificity. However, because natural proteins 
are not evolved for utilization as drugs, lead optimization is frequently beneficial for 
development of a protein therapeutic. Modifications can influence the mechanism of 
action, side effects and efficacy, and satisfy practical constraints such as production costs, 





Table I.5: Engineered protein therapeutics on the marketa 
Name Family Indication Modification Property 
Proleukin® 
(aldesleukin) 




IFN-β Multiple sclerosis Mutated free cysteine Decreased aggregation 
Humalog® (insulin 
lispro) 
Insulin Diabetes Monomer not hexamer Fast acting 
NovoLog® (insulin 
aspart) 
Insulin Diabetes Monomer not hexamer Fast acting 
Lantus® (insulin 
glargine) 
Insulin Diabetes Precipitates in dermis Sustained release 





Cancer Fusion Targets cancer cells 
PEG-Intron® 
(peginterferon alfa-2b) 








G-CSF Leukopenia PEGylation Increased serum half-life 
Oncaspar® 
(pegaspargase) 




Epo Anemia Additional glycosylation 
sites 




Growth hormone Acromegaly PEGylation; binding site 
mutations 
Novel mode of action; increased serum half-
life 




1.3.4 Structure-based design of altered specificity 
 For almost two decades, drug discovery and optimization efforts have utilized 
protein crystallographic methods to aid compound design. The target-based approach to 
drug discovery enables protein targets to be generally classified by both functional and 
structural characteristics. Drug design, also sometimes referred to as rational drug design 
or structure based drug design, is the inventive process of finding new medications based 
on the knowledge of the biological target(Gohlke et al., 2000).  
 Using a refined X-ray structure as a starting point for modeling the interaction 
between a protein and its ligands, several designed mutations that alter the substrate or 
cofactor specificity of an enzyme have been successfully made and tested during the past 
years e.g. substrate specificity of -lytic protease has been changed (Bone et al., 1989; 
Conley et al., 2011; Huang et al., 2011; Huang et al., 2010; Kuwada et al., 2011; Lippow 
et al., 2010; Pan et al., 2010; Pleiss, 2011; Ren et al., 2011; Vouilleme et al., 2010). 
Improvement of thermo stability of the truncated fibrobacter succinogenes 1,3-1,4-β-d-
glucanase (Huang et al., 2011), development of an artificial, tri-pedal, protein-based 
motor to move unidirectionally along a linear track (Kuwada et al., 2011), application of 
protein design in metabolic engineering(Pan et al., 2010; Pleiss, 2011), and innovative 
two-helix small protein scaffold as a novel and robust platform for imaging and therapy 
applications (Ren et al., 2011). 
  Most of these studies have relied on pairs of existing homologous proteins with 
different binding specificities examination of the differences in their amino acid 
sequences (in the context of a high-resolution structure of the protein) has provided the 
basis for the mutant designs.  
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 The power of structure-based rational design is most impressive when it is used to 
generate novel mechanisms of action. In some cases, increasing the binding affinity for a 
target protein can produce an increase in biological activity. In other cases, it is possible 
to reduce undesired biological activities by decreasing the affinity for non target 
molecules. Many of the reported changes in substrate specificity have arisen fortuitously 
in the course of experiments designed to probe the basis of catalytic activity. Here below 
are a few examples for such strategy for the development of novel functions. 
 
1.3.4.1 Engineering the substrate specificity in the cAMP-dependent protein kinase 
 The nucleotide activator specificity of cAMP-dependent protein kinase has been 
altered by a single amino acid change designed on the basis of predicted structural 
differences between homologous enzymes (Shabb et al., 1990). The cAMP kinase, a key 
regulatory mammalian enzyme, strongly prefers cAMP over cGMP as an activator, 
whereas the enzyme cGMP kinase shows the reversed specificity. Both proteins are 
homologous to the cAMP-binding catabolite gene activator protein, a bacterial protein 
whose structure has been determined crystallographically. Although most binding site 
residues are conserved, one amino acid appears to play a critical role in distinguishing 
between ligands: Ala334 in the cAMP-dependent enzyme is predicted to make no 
significant contacts with the nucleotide. The Ala334Thr substitution was made for the 
cAMP kinase, and its effects on specificity monitored. Whereas the wild-type protein 
productively binds cAMP with 200-fold higher affinity than cGMP, the engineered 
mutant actually has a 16-fold higher affinity for cGMP than for cAMP (Shabb et al., 
1990). This example demonstrates the power of using the information contained in a 
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protein structure to relate known functional differences between homologous enzymes to 
their amino acid differences.  
1.3.4.2 Engineering substrate specificity in alcohol dehydrogenase I 
 In many cases in which substrate specificity has been altered by directed 
mutagenesis, the engineered enzymes show much broader specificity than their wild-type 
precursors. In some instances, this broadened specificity has been anticipated (hoped for) 
and engineered into the design. Independent work on Saccharomyces cerevisiae alcohol 
dehydrogenase I (Creaser et al., 1990) and Bacillus stearothermophilus L-lactate 
dehydrogenase (Wilks et al., 1990), using homology modeled structures of the proteins to 
design mutations, has yielded engineered enzymes, which efficiently use a wide range of 
substrates to catalyze the same basic reaction. 
 Past success of protein design and engineering strategies provide not only 
invaluable lessons but are also a useful resource. Similar to these examples of protein 
engineering, our objective was to ultimately apply the structure based drug design 
approach on one of the most important class of enzymes i.e. proteases/protease inhibitors. 
We hope to understand sufficiently the relationship between structure and function so that 
we can rationally alter enzyme specificity at will. Although attaining such a state of 
enlightenment still eludes us, the success of recent structure-based experiments is quite 
encouraging. Specific targeting of protease function is achieved through tight regulation, 





1.3.4.3 Engineering the substrate specificity in proteases inhibitors 
 Proteases have an important role in many signaling pathways, and represent 
potential drug targets for diseases ranging from cardiovascular disorders to cancer, as 
well as for combating many parasites and viruses (Adams and Kauffman, 2004). 
Although inhibitors of well-established protease targets such as angiotensin-converting 
enzyme and HIV protease have shown substantial therapeutic success, developing drugs 
for new protease targets has proved to be challenging in recent years (Turk, 2006b).   
 The protein engineering of proteases and protease inhibition is pursued for several 
reasons. The application of both site-directed and random mutagenesis technologies to 
the study of a specific protease or protease inhibitor has the potential to provide a wealth 
of structural, mechanistic and functional information, regarding that specific protein 
(Watzke et al., 2008). The questions that could not be even asked 10 years ago can now 
be answered by these techniques and, from the answers, even more challenging questions 
are developed. It is a common feature of protein engineering studies that each 
experiment, whether the outcome is positive or negative, has the potential to provide 
additional insight into protein structure-function relationships. Thus, for example, 
information regarding the enhanced stability of a protease obtained through protein 
engineering can be used to understand the general principles underlying protein stability.  
 Natural inhibitors of proteases are often characterized by broad selectivity and 
they can inhibit multiple related proteases. Protein engineering efforts using natural 
inhibitors as a starting point have yielded selective inhibitors. As an example, the classic 
thrombin inhibitor hirudin, initially isolated from the medicinal leech, led the way to 
selective thrombin antagonists.  
 33 
 
 Another example is ecotin, a natural Escherichia coli protein that can inhibit 
multiple trypsin-fold proteases and has been engineered, using a library display approach, 
to create a potent and selective inhibitor of plasma kallikrein (Stoop and Craik, 2003). 
The Kunitz domain, present in many natural protease inhibitors, has also been a focus of 
protein engineering efforts to generate specific protease inhibitors86. In fact, a Kunitz 
domain-based inhibitor of plasma kallikrein, ecallantide (Kalbitor; Dyax) has recently 
been approved for the treatment of hereditary angioedema (Levy and O’Donnell, 2006).  
 The macromolecule approach of developing protease inhibitors has the distinct 
advantage over the small-molecule approach in that the former can target larger surfaces 
on the protease and may yield more selective inhibitors. Structural studies of a protein-
based inhibitor in complex with its specific protease could provide insights for the 
rational design of small-molecule inhibitors that mimic the binding interactions in terms 
of overall chemical architecture. 
 Serine proteases are among the first enzymes to be studied extensively (Neurath, 
1985). Interest in this family has been maintained in part by an increasing recognition of 
their involvement in a host of physiological processes. In addition to the biological role 
played by digestive enzymes such as trypsin, serine proteases also function broadly as 
regulators through the proteolytic activation of precursor proteins (Neurath, 1984; Van de 
Venet al., 1993). Examples of this regulation include the processing of trypsinogen by 
enteropeptidase to produce active trypsin (Jing et al., 1999) and the cascades of zymogen 
activation that control blood clotting (Davie et al., 1991).On the basis of the known 
structures of the serine proteases, changes have been engineered into serine protease 
inhibitors (SPIs) in order to modify their specificities (Table.1.6). 
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Table I.6: Examples of successful strategies applied for the design and development of 






















Peptidic (Matheson and 
Goa, 2000) 








Adopted with modification from (Drag and Salvesen, 2010). 
  
 The evolutionary mechanisms of SPIs serve to increase their variety and expand 
their functions, thus helping to meet the demands of the repertoire of endogenous and 
exogenous SPs an organism encounters. More importantly, the structural changes of a 
protease inhibitor in complex with its target protease can provide useful information on 
the interaction between the two proteins, thus allowing the development of analogs of 
that inhibitor with increased affinity towards the protease to achieve greater inhibition 
capacity. This motivated us to modify the selectivity of a serine protease inhibitor from 
Carcinoscorpius rotundicauda (CrSPI-1-D1) to specifically target thrombin. The details 




1.4  OBJECTIVES 
 There are two target proteins, Cr-TRP16 and Cr-SPI-1-D1, in this thesis. Both 
proteins are from Carcinoscorpius rotundicauda (Cr). The first part of the thesis (Chapter 
II) deals with the structural and functional characterization of a thioredoxin like protein 
16 , whereas the second part of the thesis (Chapter 4) **be careful. Some place you are 
writing Chapter II (Roman) and in other places you write Chapter 4 (Arabic); be 
consistent and use only Arabic everywhere. represents the best example of a structure 
based protein engineering approach to modify the substrate specificity of a serine 
protease inhibitor (SERPIN). Thus the specific objective of this thesis is two-fold: 
1. Structural and functional characterization of Cr-TRP16 (Chapter 2): 
a) To solve the NMR structure of Cr-TRP16 
b) To characterize the role of Cys15 in dimer formation of Cr-TRP16 
c) To delineate the mechanism of interaction between Cr-TRP16 and NF-kB 
d) To solve the X-ray structure of TXNL-6 (Chapter-3) 
2.  Structure based protein engineering approach to modify the substrate specificity 
of a SERPIN (Chapter 4):  
a) To solve the X-ray structure of Cr-SPI-1-D1 
b) To evaluate how rational structure based protein engineering strategy 




CHAPTER-II: NMR STRUCTURE OF carcinoscorpius rotundicauda 
THIOREDOXIN-RELATED PROTEIN 16 AND ITS ROLE IN 
REGULATING NF-KB ACTIVITY 
 
2.1  INTRODUCTION 
 Reactive oxygen species (ROS) are natural byproducts of several oxidative 
metabolic pathways and are known to mediate intracellular signaling pathways (Valko et 
al., 2007). However, excessive production of ROS is detrimental to the cell, due to 
increased oxidative stress (Marnett, 2000). Thioredoxin (Trx) plays a key role in 
maintaining an intracellular redox state, which is essential for protecting cells from 
oxidative damage (Nordberg and Arner, 2001). Trx is a 12 kDa ubiquitous and 
evolutionarily conserved protein in almost all organisms and functions as a disulfide 
reductase (Arnér and Holmgren, 2000; Holmgren, 1995). A conserved Cys-X-X-Cys 
sequence at the active site of Trx is involved in either reducing disulfide bonds or 
oxidizing sulfhydryls, both intra and extracellularly (Powis and Montfort, 2001b). The 
two cysteines are maintained in a reduced active form by thioredoxin reductase (TrxR), a 
selenocysteine-containing protein that uses the reducing power of NADPH (Powis and 
Montfort, 2001b). The disulfide reductase activity and reduction potential of the cysteines 
depend largely on the identity of the two XX residues (Carvalho et al., 2006).  
 Trx proteins also function as a redox sensor and transducer that impart 
information on the cellular redox status to proteins that do not possess their own redox-
sensitive residues. For instance, the reduced form of Trx1, a mammalian cytosolic 
isoform, binds to and thereby inhibits the activity of apoptosis signal-regulating kinase 1 
(ASK1), an upstream activator of the c-Jun N-terminal kinase (JNK) and p38 mitogen-
activated protein kinase (MAPK) signaling pathways (Liu et al., 2000). Their alterations 
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have been implicated in cardiovascular diseases (Aviram, 2000), diabetes (Davi et al., 
2005), hepatic and renal diseases (Seki et al., 2002), Alzheimer's disease (Nunomura et 
al., 2006), Parkinson's disease (Wood-Kaczmar et al., 2006) and rheumatoid arthritis 
(Hitchon and El-Gabalawy, 2004). Some human cancers show greatly increased Trx 
expression (Fujii et al., 1991; Gasdaska et al., 1994), indicating a potential role of Trx in 
tumorigenesis. Its interactions with different proteins of the metabolic and signaling 
pathways make Trx an attractive target for therapeutic interventions.  
 There are several Trx-like proteins, which possess the thioredoxin fold and 
function, and exist in different sizes (12-32 kDa). Recently, a 16 kDa protein that 
contains a WCPPC motif has been isolated and characterized from a species of the 
horseshoe crab, Carcinoscorpius rotundicauda, and named as Trx-related protein 16 (Cr-
TRP16) (Wang et al., 2007). Notably, 16 kDa Trx-like proteins are functionally similar to 
the 12 kDa Trxs and contain two Cys residues at the active site. Unlike other 16 kDa Trx 
like proteins, Cr-TRP16 contains an additional Cys residue (Cys15, at the N-terminus) 
but it lacks the extra C-terminal Cys residue, which is found in mammalian Trxs 
(Weichsel et al., 1996b).  
 A subtle balance between oxidants and antioxidants in the cell is crucial for 
homeostasis. There is emerging evidence that the highly conserved intracellular redox 
state regulates the mechanisms of signal transduction and gene expression (Sen and 
Packer, 1996). NF-B is one of the redox-regulated proteins. It is a member of the Rel 
family of transcription factors and exists in the cytoplasm in complex with its inhibitor 
protein, IB (Verma, 2004). A wide variety of stimuli, including TNF-α, phorbol ester, 
bacterial lipopolysaccharide, and virus infection, can activate NF-B (Menon et al., 
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1995). NF-B activation involves site-specific phosphorylation of IB-α which results in 
the dissociation of the complex, unmasking of the NF-kB nuclear localization signal and 
nuclear entry of NF-B to bind to its cognate DNA (Zabel and Baeuerle, 1990). Thus, for 
the stimuli that potently and rapidly modulate the nuclear activity of NF-B, the IB-α 
may represent a critical activation target (Verma, 2004). Several studies have suggested 
that Trx is a specifically potent antioxidant for NF-B activation (Schenk et al., 1994). 
Similar to human Trx1, Cr-TRP16 also up-regulates the TNFα-induced NF-κB activation.  
  Cr-TRP16 exists as a dimer in the oxidized state. However, the underlying 
mechanism of dimerization and the regulation of NF-κB by Cr-TRP16 are so far 
unknown, for example, what is the physiological role of the Trx-dimer? Is Cys15 
involved in Cr-TRP16 dimer formation? How is NF-κB regulated under oxidized and 
reduced cellular environments? It is possible that the oxidant-induced dimerization 
facilitates the sensing of cellular oxidative stress. Dimerization might remove Trx from 
the redox cycle, which is catalyzed by TrxR since the dimer is not a suitable substrate for 
TrxR. In addition, dimerization of secreted Trx in the relatively oxidizing extracellular 
environment could be a way of limiting the growth stimulating effects of Trx (Ren et al., 
1993). Thus, characterization of Trxs and Trx-like proteins from different organisms will 
enhance the understanding of redox controls, which is another important oxidoreductase 
(Holmgren, 1989b). 
  In order to understand the NF-κB regulation by Cr-TRP16 and to address the 
above questions, we had undertaken the structural and functional characterization of Cr-
TRP16, the first Trx fold structure from an arthropod. In this chapter we report the NMR 
structure of the reduced form of wild-type Cr-TRP16. Moreover the role of the Cys15 
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residue in dimerization and NF-κB regulation was studied by site-directed mutagenesis, 
biophysical and immunoprecipitation techniques. 
 
2.2  EXPERIMENTAL PROCEDURES 
2.2.1 Cloning  
 The full length Cr-TRP16 gene (encoding residues Met1-Arg143) was PCR 
amplified using a forward (CAGCATATGATGGAATTTATCCAAGGAAT) and a 
reverse (CCTCTCGAG TCTTGCCCAGTT) primer with an NdeI restriction site at the 5΄ 
end and an XhoI site at the 3΄ end (underlined), respectively and inserted into the pET-
22b (+) vector (Invitrogen), which was previously linearized by the corresponding 
restriction enzymes. For mammalian expression, the Cr-TRP16 gene was PCR amplified 
with the following primers: Forward: GGAGGATCCATGGAATTTATCCAAGGA and 
Reverse:ATTCTCGAGTCATTTGTCGTCATCGTCCTTATAGTCTCTTGCCCAGTTC 
TGGAA that contained BamHI and XhoI restriction sites (underlined), respectively. The 
reverse primer introduced a FLAG tag at the C-terminus of the Cr-TRP16 protein. The 
insert was ligated into the previously linearized expression vector pcDNA3.1/V5-
His/lacZ (Invitrogen). 
 
2.2.2 Protein expression and purification  
  The pET22b:Cr-TRP16 construct was transformed into the bacterial strain E. coli 
BL21 (DE3) for expression. Optimal expression of the Cr-TRP16 protein was achieved 
by induction with 0.3 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) of 1 liter 
culture at 20 ºC. Cells were disrupted by a French press and the supernatant was collected 
after centrifuging at 10,000 g for 1 h at 4 ºC. His-tagged Cr-TRP16 proteins were purified 
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in two steps using Ni-NTA (Qiagen) affinity chromatography followed by a Superdex-75 
gel filtration column on Akta Express (GE Healthcare). The buffer was exchanged to a 
solution containing 10 mM Tris (pH 7.0), 100 mM NaCl, 5 mM dithiothreitol, 5% 












C-glucose as a sole source of nitrogen and carbon, 
respectively. Weakly aligned 
15
N-labeled sample was prepared by the addition of 8 mg 
ml
-1
 of filamentous phage Pf1 (from ASLA biotech company) for residue dipolar 
couplings (RDCs) measurement. 
 
2.2.3 NMR experiments and structure determination 
  All NMR experiments were carried out at 25 °C on a Bruker Avance 800 MHz 







assignments were performed by measuring the 3D HNCACB, 3D CBCACONH (Bax and 
Grzesiek, 1993) and 3D CCH-TOCSY (Fesik et al., 1990) spectra. Inter-proton distance 
restraints for structural calculation were obtained from 3D 
13
C-edited NOESY-HSQC, 3D 
15
N-edited NOESY-HSQC and 2D NOESY spectra using a 100 ms mixing time. 
1
DNH 
RDCs were measured using the IPAP method (27). The RDC values were obtained by 
subtracting the reference value in isotropic solution.Two- and three-dimensional NMR 
spectra were processed using the NMRPipe program (Delaglio et al., 1995) and data 
analysis was performed with the help of the Sparky program(Kneller and Kuntz, 1993) 
.The structure was calculated using the Xplor-NIH 2.24 software package (Schwieters et 
al., 2003). For the final Cr-TRP16 three-dimensional structure calculation, a total of of  
1731 NOE distance restraints, 76 hydrogen bonds and 124 dihedral angle restraints that 
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were predicted by the TALOS program were (Cornilescu et al., 1999b) used. RDCs were 
used in the final cooling stage.  At each stage, 100 structures were calculated using 
30,000 steps of simulated annealing, and a final ensemble of 20 lowest energy structures 
was selected for figure preparation.. 
 
2.2.4 Site-directed mutagenesis  
 The NMR structure of Cr-TRP16 showed that Cys15 is located on the surface and 
it has been hypothesized to be involved in dimerization. This residue was mutated to 
serine in both the pET22b and pcDNA3.1/V5-His/lacZ constructs by the use of the 
inverse PCR based mutagenesis protocol (Ochman et al., 1988). The C15S mutant protein 
was expressed following the steps that were described for the wild type protein. 
 
2.2.5 Analytical Ultra Centrifugation (AUC)  
  The dimeric state of affinity and gel filtration, followed by reverse phase HPLC, 
purified WT and C15S mutant Cr-TRP16 proteins was investigated by monitoring their 
sedimentation properties in sedimentation velocity experiments. 500 µl of samples at 
OD280nm of 0.8 in 10 mM Tris-HCl (pH 7.0), 100 mM NaCl and 5% glycerol were used. 
Experiments were carried out in the absence of DTT in the buffer. Sedimentation velocity 
profiles were collected by monitoring absorbance at 280 nm. The samples were 
centrifuged at 40,000 rpm at 20 °C in a Beckman Optima XL-I centrifuge fitted with a 
six-hole AN-60 rotor and double-sector aluminum centerpieces and equipped with 





2.2.6 Western blotting 
  The human cervical epithelial carcinoma (HeLa) cell line was obtained from the 
American Type Culture Collection (Manassass, VA). Cells were cultured in the Rosewell 
Park Memorial Institute (RPMI 1640) medium containing 1X antibiotic-antimycotic 
solution with 10% FBS. The HeLa cells that were transfected with the Cr-Trp16 or C15S 
Cr-Trp16 plasmids were lysed in lysis buffer [20 mM Tris (pH 7.4), 250 mM NaCl, 2 
mM EDTA (pH 8.0), 0.1% Triton X-100, 0.01 mg/ ml aprotinin, 0.005 mg/ ml leupeptin, 
1 mM PMSF, and 4 mM NaVO4]. Lysates were then spun on a microfuge at 14,000 rpm 
for 10 min to remove insoluble material and resolved on 10% SDS gel. Nuclear protein 
extracts were prepared using a nuclear extraction kit (Active Motif, CA) according to the 
manufacturer’s instructions. Protein concentration was determined with Bradford reagent 
and 30 µg of nuclear or cytoplasmic extract was taken for immunoblotting. After 
electrophoresis, proteins were electro transferred to a nitrocellulose membrane, blocked 
with 5% nonfat milk, and probed with the antibodies of interest overnight at 4 °C. The 
blot was washed, exposed to horseradish peroxidase (HRP) conjugated secondary 
antibodies for 1 h, and finally examined by chemluminescence (ECL; Amersham 
Pharmacia Biotech). 
 
2.2.7 NF-B DNA binding assay 
 To determine NF-B activation, we performed DNA binding assay using the 
TransAM NF-B kit (Active Motif, CA), according to the manufacturer’s instructions 
and as previously described (Renard et al., 2001). Briefly, HeLa cells were transfected 
with the Cr-Trp16 or C15S Cr-Trp16 plasmids for 30 h and then stimulated with TNF- 
(1 nM) for 6 h. Nuclear protein extracts were prepared using the nuclear extraction kit 
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(Active Motif, CA), according to the manufacturer’s instructions. Protein concentration 
was determined with the Bradford reagent and 20 µg of nuclear extract was added to the 
plates precoated with an NF-B consensus oligonucleotide sequence and incubated at 
room temperature for 1 h with continuous shaking at 100 rpm. The plates were washed 
and incubated with a p65 primary antibody for 1 h at room temperature. After the final 
incubation with a secondary antibody, the wells were then washed with washing buffer; 
color was developed by the addition of substrate solution and read after 10 min at 450 nm 
against a blank, which was read at a reference wavelength of 655 nm. 
 
2.2.8 NF-κB dependent luciferase reporter assay 
 The NF-κB dependent reporter gene expression assay was performed as described 
previously (Mukhopadhyay et al., 2001). Briefly, about 10
5 
per well HeLa cells were 
plated in ninety six-well plates in RPMI buffer containing 10% FBS. The NF-κB-
responsive elements, linked to a luciferase reporter gene plasmid, were transfected with 
the wild type CR-TRP16 or C15S Cr-TRP16 plasmids. Transfection was performed using 
Lipofectamine (Invitrogen), according to the manufacturer's protocols. After 30 h of 
transfection, HeLa cells were treated with TNF-α (1 nM) for 6 h and then washed and 
lysed in luciferase lysis buffer (Promega). Luciferase activity was measured by a Tecan 
(Durham, NC) plate reader, which is equipped with a function to measure luminescence 
by using a luciferase assay kit (Promega) and was normalized to β-galactosidase activity. 
All luciferase experiments were performed in triplicate. 
 
2.3  RESULTS 
2.3.1 Purification of recombinant Cr-TRP16 
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 For the expression of pET22b, the Cr-TRP16 construct was transformed into the 
bacterial strain E. coli BL21 (DE3). Optimal expression of the Cr-TRP16 protein was 
achieved by induction of 1 liter culture with 0.25 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) at 20 °C. Cells were disrupted by a French press and the 
supernatant was collected after centrifuging at 10,000 g for 1 h at 4 °C. The His-tagged 
Cr-TRP16 protein was purified in two steps using Ni-NTA (Qiagen) affinity 
chromatography, followed by a Superdex 75 gel filtration column on Akta Express (GE 
Healthcare) (Fig. 2.1). The buffer was exchanged to a solution containing 10 mM Tris 
(pH 7.4), 150 mM NaCl, 5 mM dithiothreitol, 5% glycerol, 1 mM EDTA and finally the 
protein was concentrated to 15 mg/ml. The quality of the protein was verified using 
native PAGE and dynamic light scattering (Dyanpro solutions) instrument. Native PAGE 





Figure II.1: FPLC profile of Cr-TRP16.After affinity purification the   
Cr-TRP16 was passed through Superdex-75 column and eluted as single 
peak, which corresponds to a molecular weight of monomeric Cr-TRP16.  
 
 
Figure II.2: Dynamic light scattering (DLS) profile of Cr-TRP16. DLS 
data of Cr-TRP16 measured for 15 mg/ml. The hydrodynamic radius and 
poly dispersity index of the Cr-TRP16 protein shows monodisperse 
homogeneous sample. 
 
2.3.2 Overall structure 
  The structure of full length Cr-TRP16 (143 aa) was solved by NMR and refined 
to a final RMSD of 0.76±0.13 Å (back bone) for 20 best structures (Fig. 2.3 A). Cr-
TRP16 consists of seven β-strands in two β-sheets (Fig.2.3 B), similar to other Trxs. The 
first β-sheet accommodates both parallel and anti-parallel strands (β7↑β6↓β3↑β4↑β5↑). 
The residues of strands β3 and β4 are mostly buried and conserved in thioredoxins. These 
residues are mostly hydrophobic and are part of a hydrophobic cluster, formed by Phe31, 
Tyr32, Phe33, Phe35, Trp37, Phe44, Tyr52, Phe62, Phe66, Phe77 Tyr79, Trp87, Tyr92 
and Tyr104. The second β-sheet, formed as a β-hairpin (β1↑β2↓), is solvent accessible 
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and carries five charged residues: Lys11, Lys12, Arg14, Glu16, and Glu21. This segment 
is highly variable among thioredoxin like proteins. The longest helix, α1 (residues 43-57), 
is located on the surface of the protein (Fig. 2.4).  
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Figure II.3: Structure of Cr-TRP16. (A) The best 20 backbone structures of reduced WT Cr-TRP16 thioredoxin after 
simulated annealing refinement. (B) The ribbon diagram of the Cr-TRP16 molecule. Cr-TRP16 consists of seven β-
strands in two β-sheets, similar to other Trxs. The first β-sheet (β1β2) is an anti-parallel β-hairpin and the second β-
sheet contains both parallel and anti-parallel strands (β7↑β6↓β3↑β4↑β5↑). There are four α-helices (α1, α2, α3 and α4). 
The active site cysteines (Cys38 and Cys41) and the N-terminal Cys15 residue that promotes dimerization are drawn as 





Figure II.4: The topology diagram of Cr-TRP16. 
 
2.3.3 Sequence and structural homology 
  Proteins with the Trx fold and conserved active site-sequence are classified under 
the Trx superfamily (Matsuo et al., 2002). Comparison of Trxs and Trx-like protein 
sequences (Fig. 2.3 A) show that the Trx core domain is well conserved with the central 
five β-strands, surrounded by four α-helices (Eklund et al., 1991a). Cr-TRP16 has an 
overall sequence identity of 18% with the 12 kDa Trxs from mammalian, insect, and 
bacterial species. Most invariant residues are clustered around the active site. The 12 kDa 
Trxs are characterized by a conserved WCGPC motif in the active site whereas Cr-





Table II.1: NMR data and structure determination details for reduced Cr-
TRP16 
Parameters  
All NOE distance restraints
a
  1728 
Intra-residue 717 
Inter-residue  
          Sequential (׀i–j׀ = 1) 435 
          Medium-range ( 1 <׀i–j׀≤5) 227 
          Long-range (׀i–j׀≥5) 349 
Hydrogen bonds restraints 76 
Dihedral angle restraints(φ, ψ )
b
 124 
Residual dipolar coupling restraints                          54 
Deviations from idealized covalent geometry
c
  
  RMSD of bond lengths (Å) 0.0021±0.00004 
  RMSD of bond angles (°) 0.3634±0.0086 
  RMSD of improper angles (°) 0.3329±0.008 
Deviations from experimental restraints  
  RMSD of distance restraints (Å) 0.0231±0.0005 
  RMSD of dihedral angle restraints (°) 0.2170±0.057 
Ramachandran plot analysis (%)
d
  
   Residues in allowed regions 95.5% 
   Residues in generously allowed regions 3.0% 
   Residues in disallowed regions 1.5% 
Average RMSD from mean structure (Å)
e
  
   All residues (2-141) 0.72±0.15 
    Regular 2° structure region 0.47±0.10 
a 
All NMR experiments were performed on a Bruker AVANCE 800 spectrometer 
equipped with a TXI cryoprobe at 25 °C. 1H, 13C and 15N resonance assignments were 
assigned by measuring the 3D HNCACB, 3D CBCACONH (Bax and Grzesiek, 1993) 
and 3D CCH-TOCSY (Fesik et al., 1990) spectra. Interproton distance restraints for 
structural calculation were obtained from 3D 13C-edited NOESY-HSQC(Görler et al., 
1999), 3D 15N-edited NOESY-HSQC(Görler et al., 1999) and 2D NOESY (Haase et al., 
2011) spectra using a 100 ms mixing time. All data were processed with NMRPipe 
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(Delaglio et al., 1995) and analyzed with SPARKY(Kneller and Kuntz, 1993). The 
distance restraints were obtained by classifying the NOE cross peaks into three 
categories: strong (1.8–2.9 Å), medium (1.8–3.5 Å), and weak (1.8–5.0 Å). Solution 
structures of Cr-TRP16 was calculated using the torsion angle dynamics simulated 
annealing method within XPLOR-NIH(Schwieters et al., 2003).  
b
 Dihedral angles of backbone ϕ and ψ were predicted by TALOS (Cornilescu et al., 
1999a) using
 
the chemical shifts of Cα, Cβ, Hα, N, and HN. 
c
 Twenty lowest-energy conformers with no NOE violations greater than 0.5 Å and no 
torsion angle violations greater than 5° were selected from 100 conformers to 
represent the NMR ensembles. 
d
 Calculated with PROCHECK-NMR (Laskowski et al., 1996). 
e 
Calculated with MOLMOL(Koradi et al., 1996); averages are over backbone atoms. 
 
 So far, no Trx structure is reported from arthropods. A search for topologically 
similar domains in the Protein Data Bank (PDB) using the DALI program (Holm and 
Sander, 1998) reveals that the structural features of Cr-TRP16 resemble a typical Trx 
(Martin, 1995a). The closest match is observed between the Trx-related protein 
tryparedoxin II (PDB code 1FG4), a 16 kDa Trx like protein from Crithidia fasciculate, 
with 26% sequence identity and an RMSD of 2.9 Å for 126 Cα atoms. The structure-
based sequence alignment reveals that most of the structurally invariant residues are 










Figure II.5: Comparison of Cr-TRP16 with Trypaerdoxin. (A) Structure based sequence comparison between Cr-TRP16 and other 
Thioredoxins. Alignment was done by Clustal W. Identical and conserved residues are highlighted in red and outlined in blue, respectively. This 
figure was created by using the program ESPript (Gouet et al., 1999). (B) Superimposition of Cr-TRP16 (red) and Trypaerdoxin II (green) (PDB 
code 1FG4) from Crithidia fasciculate. The alignment was performed using the program COOT (Emsley and Cowtan, 2004). The RMSD 




2.3.4 Dimerization of Cr-TRP16 
  Human 12 kDa Trx1 forms a homodimer through an intermolecular disulfide 
bond via Cys73 (Weichsel et al., 1996a). Interestingly, Cr-TRP16 can also form a stable 
dimer. Despite low sequence identity (18%) between Cr-TRP16 and hTrx1, Cr-TRP16 
could also enhance TNFα-induced NF-κB transcriptional activation by increasing the NF-
κB DNA-binding activity. In addition to the two conserved Cys residues (Cys38 and 
Cys41) at the active site, Cr-TRP16 has an additional Cys residue at position 15, which is 
involved in the formation of an intermolecular disulphide bond. The previous report 
(Wang et al., 2007), based on mass spectrometry, has shown that only the two conserved 
Cys residues at the active site are redox active, similar to human Trx1.  
 
2.3.5 1H- 15N-HSQC NMR spectroscopy 
  In order to characterize the mode of dimerization and to identify the critical 




N-HSQC NMR spectra of reduced and 
oxidized wild type Cr-TRP16 were compared. Sequential assignments were completed by 





N-HSQCNMR spectra of reduced and oxidized Cr-TRP16 are shown in 
Figs. 2.6 A and 2.6 B, respectively. 2D NMR experiments show that the majority of the 
amides are unaffected by dimerization. Fig. 2.6 B shows a total of 26 amide signal 
chemical shifts have changed. Nearly all of these residues are located in the surface 
exposed region around the N-terminus Cys15 and the second β-sheet (β1β2). This 











Figure II.6: Superposition of 1H-15N HSQC spectra of oxidized and reduced wild type Cr-TRP16 1H-15N 
HSQC spectra of CrTRP16 in its (A) reduced and (B) overlay of oxidized and reduced forms. Backbone amide 
resonances are labeled according to sequential assignments. Lines indicate shifts displayed by amino acid 
residues participating in the interactions leading to dimerization. The spectra were acquired at 303 K in 10 mM 





2.3.6 Analytical ultracentrifugation (AUC) 
  The Cys15Ser (C15S) mutant was generated to elucidate the role of the 
additional Cys at position 15 (Cys15) in dimer formation and its physiological 
significance in the NF-κB function. Dynamic light scattering (DLS) measurements on 
reduced and oxidized C15S Cr-TRP16 show an apparent molecular weight corresponding 
to only a monomer. Non-reducing and SDS PAGE for C15S Cr-TRP16 show a single 
band at an apparent molecular weight of 17 kDa (Fig. 2.7 B), whereas non-reducing 
PAGE for the wild type protein shows an apparent dimer (34 kDa) band. In the AUC 
analysis of the oxidized wild type Cr-TRP16 protein (0.8 OD at 280 nm), there is only 
one peak corresponding to an apparent molecular weight of a dimeric Cr-TRP16 (34 kDa, 
Fig. 2.7Ai) while the reduced Cr-TRP16 protein shows a peak at 17 kDa, corresponding 
to monomeric Cr-TRP16 (Fig. 2.7Aii). On the other hand, we observe only one peak with 
an apparent molecular weight of 17 kDa for both the oxidized and reduced (Fig. 2.7B) 
C15S mutant of Cr-TRP16. These results are in agreement with our hypothesis that 










Figure II.7: Study of the dimerization of Cr-TRP16 by sedimentation velocity analysis.The experiments were conducted in 
TRIS buffer (Tris-HCl 10 mM pH 7.0, 100 mM NaCl, and 5% glycerol) at a rotor speed of 40,000 rpm, and a rotor 
temperature of 20 ºC. The experiments were carried out in the absence of DTT in the buffer. The sedimentation velocity 
profiles were collected by monitoring the absorbance at 280 nm. (A) SDS-PAGE analysis of Cr-TRP16 dimerization. . 
FPLC purified Cr-TRP16 was subjected to reversed-phase HPLC by using a C8 column. The separated proteins  were 
analyzed by SDS-PAGE and coomassie blue staining under nonreducing (–DTT) and reducing (+DTT) conditions, as 
indicated. Lanes 2 and 3 represent oxidized  and  reduced  wild  type  Cr-TRP16,  respectively,  under  a  non-reducing  
condition. Similarly lanes 4 and 5 represent C15S mutant Cr-TRP16 under a non-reducing condition. Lanes 5 to 8 represent 
similar loading patterns under a reducing (+DTT) SDS-PAGE condition as indicated earlier. A molecular marker is shown 
at Lane 1 of the gel. This analysis shows that only wild type Cr-TRP16 can form a dimer. (B) Molecular weight profile of (i) 
oxidized and (ii) reduced wild type Cr-TRP16. (C) Molecular weight profile of oxidized C15S Cr-TRP16 mutant. The scans 




2.3.7 Cr-TRP16 increases TNF- induced nuclear translocation of p65 and p50 
 Biophysical and mutational studies have confirmed that Cr-TRP16 exists as a 
dimer and Cys15 is responsible for its dimerization. However, it is unclear whether Cr-
TRP16 exists as a dimer under physiological conditions. In order to address this, we 
expressed wild type and C15S mutant Cr-TRP16 proteins, and stimulated the cells with 
TNF-, one of the most potent inducers of NF-B activation (Sethi and Tergaonkar, 
2009). Western blot analysis with anti-p50 antibody revealed minimal change in the NF-
κB p50 protein, suggesting that the overexpression of Cr-TRP16 does not change the 
expression of p50 (Fig. 5A). Similarly, it does not show any significant effect on the 
TNF- induced IB degradation (Fig. 5A). Subsequently, we investigated the effect of 
Cr-TRP16 overexpression on nuclear translocation of NF- κB. Western blot analysis with 
nuclear extract using anti-p50, anti-p65 and anti-phosphorylated p65 antibodies revealed 
that the overexpression of wild type Cr-TRP16 induced the nuclear translocation of the 
p50-p65 heterodimer and increased the level of phosphorylated p65 while no appreciable 







Figure II.8: Effect of Cr-TRP16 on the expression and subcellular 
localization of NF-κB. (A) Effects of Cr-TRP16 expression on NF-κB 
p50, p65 and IκBα expression. HeLa cells were transfected with Cr-
TRP16 as described in materials and methods. Whole cell lysates were 
subjected to Western blot analysis. The FLAG-tagged Cr-TRP16 was 
detected with anti-FLAG antibody. (B) and (C) HeLa were transfected 
with the plasmids Cr-TR16 or C15S Cr-TRP16 for 30 h and then 
stimulated with TNF- (1 nM) for 6 h. Nuclear and cytoplasmic protein 
extracts were prepared using nuclear extraction kit (Active motif, CA) 
according to the manufacturer’s instructions. Protein concentration was 
determined with Bradford reagent. The nuclear and cytoplasmic extracts 






2.3.8 Cr-TRP16 augments TNF- induced NF-B DNA binding activity 
  Next we investigated the effect of wild type and the C15S mutant Cr-TRP16 on 
NF-B DNA binding activity. Nuclear extracts were prepared and tested for NF-B 
activity using an ELISA based DNA binding assay. Fig. 2.9A represents the effect of Cr-
TRP16 on constitutive NF-B DNA binding activity. This result demonstrates that Cr-
TRP16 does not activate NF-B on its own but enhances TNF--induced NF-B 
activation. As shown in Fig. 6B, wild type Cr-TRP16 increases TNF- induced NF-B 
DNA binding activity while there is no significant change observed in the C15S Cr-
TRP16 transfected cells. These results clearly indicate that over expression of Cr-TRP16 







Figure II.9: TNFα induced NF-κB DNA-binding activity. (A) TNF-α 
induced NF-κB DNA-binding activity. HeLa cells were transfected with 
indicated amounts of wild type and mutant (C15S) Cr-TRP16 for 30 h and 
then stimulated with TNF- (1 nM) for 6 h. Nuclear extracts from HeLa 
cells stimulated with TNF- were assayed for NF-κB p65 activation. 
Nuclear protein extracts were prepared using a nuclear extraction kit 
(Active motif, CA) according to the manufacturer’s instructions and 
assayed for NF-κB p65 activation using the TransAM NFκB p65 kit. (B) 
Effect of over expression of Cr-TRP16 on the NF-κB activity. HeLa 
cells were transfected with indicated amounts of wild type and C15S Cr-
TRP16 along with NF-B regulate luciferase reporter construct and co-
transfected with -galactosidase vector. Luciferase activity was measured 
using luciferase assay kit (Promega). Relative light units were measured 
by Tecan (Durham, NC) plate reader with function to measure 
luminescence and the data was normalized to β-galactosidase activity. All 
luciferase experiments were done in triplicate and repeated three or more 
times.  
 
2.3.9 Cr-TRP16 augments TNF- induced NF-B-dependent reporter gene 
expression  
 Although we observe that Cr-TRP16 increases NF-B activation in the NF-B 
DNA binding assay, DNA binding alone does not always correlate with NF-B-
dependent gene transcription, indicating there could be some additional regulatory steps 
(Ahn et al., 2007). To determine the effects of Cr-TRP16 on TNF- induced NF-B 
dependent reporter gene expression, we transiently transfected HeLa cells with Cr-TRP16 
or C15S Cr-TRP16 along with NF-B to regulate a luciferase reporter construct and co-
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transfected with a -galactosidase vector. A 2-fold increase in luciferase activity was 
observed after stimulation with TNF- alone (Fig. 2.9 C) while the wild type Cr-TRP16 
transfected HeLa cells show a 6-fold increase in TNF- mediated NF-B dependent 
luciferase expression. Interestingly, no significant effect was observed in the cells 
transfected with C15S Cr-TRP16. These results show that Cr-TRP16 can potentiate TNF-
 inducible NF-B-dependent reporter gene expression.  
      Overall, our results clearly demonstrate that the Cys15 residue is crucial for the 
dimerization of Cr-TRP16 and only the dimeric form plays a pivotal role under 






Figure II.10: Model for the interaction of Cr-TRP16 dimer with NF-κB 
dimer.Based on the previously published human NF-κB p50 
homodimer:DNA complex and human Trx: NF-κB p50 peptide complex 
structures and our structural, biophysical and biochemical results, we 
propose that Cr-TRP16 forms a homodimer by making a disulfide link 
through Cys15 and is likely to occupy the location where DNA binds to 
NF-κB. The active site motif WCPPC of Cr-TRP16 (through Cys38 and 
Cys41) is likely to interacts with the redox active Cys 62 of NF-kB dimer. 
For the ease of residue numbering, a p50 homodimer is assumed for NF-
κB and the C-terminal cysteines of NF-κB which promote dimerization of 





2.4  DISCUSSION 
 Sequence alignment reveals that the catalytic WCPPC motif is evolutionarily 
conserved and indicates the potential importance of this motif even in 16 kDa Trx-like 
proteins. Although the active site of the 16 kDa Trx-like proteins in mammals has 
undergone marked changes, several other regions remain well conserved, when compared 
to 12 kDa Trxs. This observation suggests that the members of the 16 kDa Trx-like 
protein family have evolutionarily diverged from the 12 kDa Trxs at an early stage from 
C.elegans to human (Wang et al., 2007). Several multi-domain Trx-like proteins have 
evolved, retaining the Trx fold (Atkinson and Babbitt, 2009). Although the Trx 
superfamily has received much attention, only a few structural and functional studies 
have been undertaken to analyze the multi-domain Trx proteins. Cr-TRP16 has a fold 
similar to that of tryparedoxin, a 16 kDa Trx-like protein from the parasitic protozoa 
Crithidia fasciculata (Trypanosoma) (Montemartini et al., 2000). In particular, the active 
site motif, CPPC, is homologous to that of the corresponding motif in the protozoan Trx-
like protein (Hofmann et al., 2001). However, functionally the Cr-TRP16 is quite 
different from the tryparedoxin. In contrast, despite notable differences in the amino acid 
sequence of the catalytic site, Cr-TRP16 appears to be functionally similar to human Trx 
(Qin et al., 1995) and regulates NF-κB activity (Wang et al., 2007).  
  While most of the 16 kDa Trx-like proteins do not have an extra cysteine, Cr-
TRP16 possesses an additional Cys residue at the N-terminus. This prompted us to 
investigate the functional significance of this Cys and hypothesize that Cr-TRP16 could 
form a homo dimer and regulate NF-κB, like hTrx1. Mutation, AUC, non-reducing SDS 
and 2D-NMR experiments confirm that only wild type Cr-TRP16 can form a dimer under 
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an oxidized condition and not the C15S mutant. However, it was unclear, whether the 
dimer or monomer is the active form in vivo. In order to clarify the physiological role of 
the N-terminal Cys15 residue of Cr-TRP16, we overexpressed the wild type and C15S 
mutant proteins in HeLa cells, stimulated the cells with TNF-α and measured NF-κB 
activation. We found that wild type Cr-TRP16 could increase the TNF-α induced NF-κB 
DNA binding activity but not the C15S mutant-transfected cells (Fig. 2.9A&B). 
 Moreover we observed a similar pattern of results in TNF-α induced NF-κB 
dependent luciferase expression in the cells that were transfected with the wild type and 
C15S mutant proteins (Fig. 2.9C). Even though the C15S mutant contains intact redox 
active Cys38 and Cys41 residues, it could not regulate the NF-B activity, suggesting 
that Cr-TRP16 exists as a dimer under the physiological condition and Cys15 is the 
crucial residue for the dimer formation. These results are consistent with our biophysical 
studies and present evidence that the dimer of Cr-TRP16 is the naturally occurring form.  
 Studies by Matthews et al. (1992) and Meyer et al. (1993) show that the DNA-
binding activity of NF-κB follows redox regulation through its modulatory Cys residues. 
Furthermore, the NF-κB components, p50 and p65, contain well-conserved cysteine 
residues in their DNA-binding loops (Ghosh et al., 1995; Muller et al., 1995). Activation 
of the DNA-binding properties of human NF-κB requires that the cysteine at position 62 
of the p50 subunit be reduced. In the p50 homodimer:DNA complex structure (Ghosh et 
al., 1995; Muller et al., 1995), the p50 homodimer binds to DNA in a channel, whose one 
end is closed by the C-terminal dimerization domain and the front is closed by two loops 
that contain Cys62, one from each subunit. If a disulphide is formed between the two 
Cys62 residues in uncomplexed NF-κB, then DNA cannot bind to the p50 homodimer. 
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Similarly, if a disulphide bridge is formed in the p50 homodimer:DNA complex, then 
DNA cannot be released (Qin et al., 1995). This implies that the activation of NF-κB 
DNA binding activity begins with IκB degradation, reduction of NF-κB by Trx followed 
by translocation of NF-κB to the nucleus (Flohé et al., 1997; Powis and Montfort, 2001a) 
for effective DNA binding and transactivation (Flohé et al., 1997). Based on this 
argument and our structure-function analyses, we propose a model on how Cr-TRP16 
could bind to the p50 homodimer or p50/p65 heterodimer in vivo (Fig. 2.10). Thioredoxin 
and glutathione reductase are responsible for maintaining a reduced environment in the 
cell. In a glutathione reductase free system, Trx and Trx-like proteins are solely 
responsible for maintaining a reduced environment. Several diseases, including cancer, 
autoimmune diseases, and infectious diseases, are mediated through the effects of Trx 
and TrxR and unbalanced NF-kB activation.  
 The structure based functional studies clearly demonstrated that (1) Cr-TRP16 
regulate NF-kB similar to 12 kDa human Trx, (2) C15 is the key residue for dimerization, 
and (3) only the dimeric Cr-TRP16 regulates Nf-kB activity. This study provides insights 
into the interactions of Trxs and Trx-like proteins with other metabolic pathways and 
their physiological relevance and will eventually lead to promising therapeutic 
development to modulate the action of Trx and NF-B. In the next chapter, we are going 
to discuss the expression and purification of human thioredoxin like protein-6 (TXNL-6), 
a homolog of Cr-TRP16 and protect retinal cells from apoptosis under stress and 
characterization of its interaction with NF-kB.  
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CHAPTER-III: CHARACTERIZATION OF HUMAN THIOREDOXIN 
LIKE PROTEIN-6 (TXNL-6) 
 
3.1  INTRODUCTION 
 Photoreceptor cell death by apoptosis is responsible for many eye diseases 
including age-related macular degeneration which is estimated to affect more than 8 
million individuals in the United States alone (Donovan and Cotter, 2002). It has largely 
been accepted that reactive oxidative species (ROS) and a series of caspase and calpain 
enzymes plays a key role in both the initiation and execution of apoptosis (Gómez-
Vicente et al., 2005). Therefore, the regulation of the cellular redox state and apoptotic 
process may serve as potential therapeutic strategies applicable to retinitis pigmentosa 
and other human retinal diseases (Sanvicens et al., 2004). 
  It has been shown that nerve growth factor-dependent activation of NF-
κB contributes to the survival of sympathetic neurons (Maggirwar et al., 1998) and the 
activation of NF-κB is necessary for the survival of S-type neuroblastoma (Bian et al., 
2002). Rod-derived cone viability factor, (RdCVF) a truncated mouse thioredoxin is 
specifically expressed by rod photoreceptor cells and prevents the apoptosis of cone cells. 
However the protective mechanism of RdCVF and the implications of its human 
homologue, thioredoxin-like 6 (TXNL6), on the apoptosis of retinal cells remain 
unknown. Recently, Leveillard et al. (Léveillard et al., 2004) showed that RdCVF, could 
slow down cone degeneration in both the chick and mouse models. However, the 
protective mechanism of RdCVF against apoptosis of retinal cells is still unknown.  
 In vertebrates, there are two families of Trxs with high homology to the 16 kDa 
Cr-TRP16; one is 16 kDa and other is 24 kDa (TRX6). However invertebrates only 
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possess the 16 kDa Trxs and bacteria are devoid of this homolog. This observation 
suggests that the 16 kDa TRXs have evolutionarily diverged from the 12 kDa Trxs at an 
early stage and the 16 kDa Trxs probably underwent gene duplication and divergence in 
vertebrates and gave rise to the 24 kDa TXNL-6 (Zhang, 2003). Interestingly, unlike the 
invariable WCPPC catalytic motif in the 16 kDa TRXs of invertebrates, the active site of 
the 24 kDa TXNL-6 of vertebrates has undergone marked changes (Fig. 1). For human 
TXNL-6, even the most conserved Cys residues have been replaced with Ser residues. It 
is therefore reasonable to postulate that the duplication and further evolution of the gene 
encoding in vertebrates have probably relaxed the selection pressures and accelerated the 
evolution of novel catalytic motifs and functions (Force et al, 1999; Zhang, 2003). 
Therefore, it is interesting to investigate if the 24 kDa TXNL-6 in mammals still conserve 
and exhibit the basic enzymatic functions of the invertebrate 16 kDa counterparts. 
Simultaneously, it would be pertinent to explore the evolutionary, structure and 
functional similarities /differences between the Cr-TRP16 and human TXNL-6.  
 It has been postulated that TXNL-6 reduces the Cys residue in the DNA binding 
motif of NF-κb to enhance its binding to the κB promoter site (Wang et al., 2008). 
However still a few questions remain unanswered. Why does TXNL-6 not appear to 
affect the accumulation of ROS in contrast to the universally expressed human Trx1, 
which prevents photoreceptor cell damage by scavenging singlet oxygen and hydroxyl 
radicals? How does TXNL-6 interact with NF-κB? In order to address these questions we 
sought to determine the crystal structure of TXNL-6 and its complex with NF-κBp50 and 
subsequent functional studies to explore and understand the mechanism of interaction 
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between them to protect the photoreceptor cells from apoptosis. Here, we report the 
expression, purification and characterization of TXNL-6 and NF-kB. 
 
3.2 RESULTS AND DISCUSSION 
3.2.1 Cloning 
  The full length TXNL-6 gene (encoding residues Met1-Phe212) was PCR 
amplified using a forward (CAG GGA TCC ATG GCC TCC CTG TTC TCT) and a 
reverse (CCT CTC GAG TCA GAA CAG CCC CCC GG) primer with a BamH-I 
restriction site at the 5΄ end and an XhoI site at the 3΄ end (underlined), respectively. The 
insert was ligated into the previously linearized pET-22b (+) expression vector 
(Invitrogen). 
 
3.2.2 Protein expression and purification 
 The pET22b: TXNL-6 construct was transformed into the bacterial strain E. coli 
BL21 (DE3) for expression. Optimal expression of the TXNL-6 protein was achieved by 
induction with 0.3 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) of 1 liter culture at 
18 ºC. Cells were disrupted by a French press and the supernatant was collected after 
centrifuging at 10,000 g for 1 h at 4 ºC. His-tagged TXNL-6 proteins were purified in two 
steps using Ni-NTA (Qiagen) affinity chromatography followed by a Superdex 75 gel 
filtration column on Akta Express (GE Healthcare). The buffer was exchanged to a 
solution containing 10 mM Tris (pH 7.4), 150 mM NaCl, 5 mM dithiothreitol, 5% 























Figure III.1: Gel filtration profile of purified TXNL-6. A.) after affinity 
purification the TXNL-6 was passed through Superdex-75 column and 
eluted as two peaks. First peak corresponds to void volume and the second 
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peak is the monomeric TXNL-6 B.) Samples from different stages of 
purification were collected, separated by 12% SDS-PAGE and visualized 
by Coomassie staining. Eluted TXNL-6 migrated in the gel with an 
apparent molecular weight of 24 kDa. Lanes: 1. Low molecular weight 
ladder; 2. Flow through after binding Ni-NTA beads; 3-7. Column washes;  
8-10. First peak of gel filtration elution; 11-14. Second peak of gel 
filtration elution. 
 
 The quality of protein was verified using Native-PAGE and Dynamic light 
scattering (Dyan pro solutions) instrument. Native-PAGE and DLS results showed that 
TXNL-6 proteins were non-homogeneous. 
 
3.2.2  Mutagenesis of surface exposed charged residues of TXNL-6 
 To enhance crystallization probability, we have carried out the mutagenesis of the 
surface exposed charged residues of cluster 1,2 and 3, as predicted by the SERp 
server[http://www.doe-mbi.ucla.edu/Services/SER](Goldschmidt et al., 2007). Due to the 
presence surface exposed charged residues, the protein could form non-specific 
intermolecular interaction which can cause aggregation, and prevent crystallization. 
Lysine  Alanine mutation has been used not only to overcome the protein aggregation 
but also to improve crystallization kinetics. We obtained monomeric TXNL-6 in 
compression to the oligomer after mutagenesis. Protein quality was improved drastically 






Figure III.2: SERp predicted surface exposed charged residues 
clusters.This summary shows 3 cluster candidate(s) that contain residues 
suitable for mutation designed to confer enhanced crystallizability. The 
cluster candidates are presented in the order of predicted success (best 
candidates with higher scores are shown first). Ideal mutation candidates 
are non-conserved, high entropy residues that lie in surface-exposed, 
entropy-rich regions of the protein. Good candidates for mutation typically 





Figure III.3: FPLC profile of TXNL-6 after surface exposed 
mutagenesis.After affinity purification the TXNL-6 was passed through 
Superdex-75 column and eluted as single peak, which corresponds to a 
molecular weight of monomeric TXNL-6.  
 
3.2.3 In vitro interaction between TXNL-6 and NF-kB   
 It has been shown that TXNL-6 forms an intermediate with various target 
molecules through disulfide linkage(Wang et al., 2008). To explore further the 
association between TXNL-6 and NF-kB p50, and to trap the physical association 
between both proteins, we used cross linking reagents such as diamide, which convert the 





Figure III.4: Dynamic light scattering (DLS) profile of mutated TXNL-
6.DLS data of TXNL-6 measured for 10 mg/ml. The hydrodynamic radius 
and poly dispersity index of the TXNL-6 protein shows monodisperse 
homogeneous sample. 
 
3.2.3.1 Cloning of NF-kBp50 protein 
 The NF-kB gene (encoding residues 1-435, 1-366, 1-244 and 43-244) were PCR 
amplified using a forward and a reverse primer with a BamH-I restriction site at the 5΄ 
end and an XhoI site at the 3΄ end , respectively. The insert was ligated into the 
previously linearized expression vector pGEX-6P-1 (GE healthcare). 
 
3.2.3.2 NF-kBp50 protein expression and purification 
 The expression vector pGEX-6P-1: NF-kB (43-244) was transformed into E. coli 
BL21 and induced with 0.2 mM IPTG at 18 ˚C overnight. The bacteria pellets were 
harvested, sonicated and lysed in 50mM Tris-HCl pH 8.0, 100 mM NaCl, 2 mM 
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dithiothreitol containing a protease inhibitors cocktail (Sigma). After binding to GST 
sepharose 4B beads and washing away all unbound proteins, the NF-kB protein was 
cleaved with thrombin and eluted from the column. The eluted protein was further 
purified on a FPLC Hiload 16/60 Superdex75 gel filtration column using an AKTA 
FPLC UPC-900 system (GE Healthcare) (Fig.3.5). Dynamic light-scattering experiments 
were performed on the purified NF-kB samples using a DynaPro (Protein Solutions) 
dynamic light-scattering instrument. 
 
 
Figure III.5: The FPLC profile of NF-κB (43-244).After affinity 
purification NF-κB (43-244) was passed through Superdex-75 column and 
eluted as a single peak, which corresponds to the molecular weight of 





3.2.3.3 Complex formation of NF-kB p50(43-244) with TXNL-6 
 To form the NF-kB p50 (43-244) / TXNL-6 complex, the purified 6XHis tagged 
TXNL-6 protein was allowed to interact with GST: NF-kB in the presence of diamide, 
which would cross link the two proteins by the conversion of free sulfhydryls to 
disulfides by cysteine oxidation(Wang et al., 2008). After extensive washing, the proteins 
were eluted from the resin by using 30 mM reduced glutathione. Subsequently, we passed 
the presumable complex through Ni-NTA resin to retain only the TXNL-6 / NF-kB 
hetero-dimer. After extensive washing, the cross-linked heterodimer was eluted by 300 
mM imidazole and further purified using a FPLC Hiload 16/60 Superdex200 gel filtration 
column using an AKTA FPLC UPC-900 system (GE Healthcare). Non-reducing SDS-
PAGE analysis shows only the hetrodimer of TXNL-6 and NF-kBp50 (43-244), (Fig. 





Figure III.6: FPLC profile of TXNL6 and NF-κB p50 complex protein. 
After affinity purification of TXNL6 and NF-κB p50 complex were passed 
through Superdex-200 column. There were two peaks in the elution 
profile. The complex was eluted as first peak in the gel filtration column 







Figure III.7: In vitro interaction between TXNL6 and NF-κB p50 subunit 
(non-reducing SDS-PAGE).GST- NF-κB(43-244), bound to glutathione 
sepharose beads, was incubated with human TXNL-6.The mixture was 
kept at 4 °C with 20 mM diamide for overnight .After elution from the 
GST-column, it was further passed through Ni-NTA beads to eliminate 
free NF-kB band. The TXNL6 and NF-κB p50 complex was finally 
purified by using a Superdex-200 column followed by Ni-NTA affinity 
purification. Samples from gel-filtration were collected, analyzed by 12% 
non-reducing SDS-PAGE and visualized by Coomassie staining. The 
eluted TXNL6 and NF-κB p50 complex migrated in the gel with an 
apparent molecular weight of 47 kDa (lane2-8). A molecular marker is 










Figure III.8: Identification of TXNL6 and NF-κB p50 elution peak by 
peptide mass fingerprint. The peptide mass fingerprint (PMF) of peak 1 
from gel-filtration (Fig. 3.7) result revealed the identity of the TXNL6 and 





3.2.4 Crystallization of TXNL-6 and its complex with NF-kB-p50 
Crystallization screens for TXNL-6 and its complex with NF-kB were setup at 4
 
and 25 °C by the hanging drop vapor diffusion method using Hampton Research 
crystallization screens, JCSG+ (Qiagen),Nextal (Qiagen) and JB crystallization screens 
(Jena Biosciences) with drops containing equal volumes (1 μl each) of reservoir and 
protein solution (12 mg/ml) against 0.5 ml of reservoir .Presently drops are under 
observation. Once, we will have crystals, structure and subsequent functional studies will 
be performed.  
 In the next chapter, we are going to discuss the structure based rational design of 





CHAPTER-IV: MODIFYING THE SUBSTRATE SECIFICITY OF 
Carcinoscorpius rotundicauda SERINE PROTEASE INHIBITOR 
DOMAIMN 1 TO TARGET THROMBIN 
 
4.1  INTRODUCTION 
The innate immune system is the first line of inducible host defense against 
various pathogens and their products (Hoebe et al., 2004). Secreted proteases serve 
important roles in pathogen virulence. Several families of protease inhibitors from the 
host play an important role in innate immunity by inactivating and clearing the proteases 
from the pathogens. Horseshoe crab hemocytes contain granules filled with several serine 
protease zymogens. During mechanical injury or pathogen invasion, the granules are 
released into the extracellular milieu by exocytosis, and precursor forms of clotting 
enzymes are activated by a serine protease cascade triggered by bacterial endotoxin. This 
pathogen induced cascade is regulated by three serpins, also known as Limulus 
intracellular coagulation inhibitors (LICI-1, LICI-2 and LICI-3) (Armstrong, 2001; Ding 
et al., 1993; Gettins, 2002; Muta and Iwanaga, 1996). Protease inhibitors, thus plays 
multiple roles by maintaining homeostasis and eliciting innate immunity (Hoffmann et 
al., 1999). This defense system is essential for the survival and perpetuation of all 
multicellular organisms (Hoffmann et al., 1999; Salzet, 2001).  
The Kazal family is one amongst 18 families of serine protease inhibitors, and is 
mainly divided into two groups: the classical and the non-classical inhibitors. Non-
classical Kazal inhibitors (Hemmi et al., 2005) consist of one to seven repeated domains, 
with each domain constituting 50-60 amino acid residues. Regardless of whether a 
domain is functionally active, it contains a reactive site loop (RSL) exposed at the 
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surface. The serine protease inhibitor functions as a substrate analogue, but the resulting 
enzyme-inhibitor complex is very stable (Kanost, 1999).
We recently reported a two-domain non-classical Kazal serine protease inhibitor 
from the hepatopancreas of Carcinoscorpious rotundicauda (CrSPI) with a possible dual 
function of inactivating pathogen protease (subtilisin) and host protease (furins). The full 
length and domain 2 of CrSPI-1 have been shown to contain full inhibitory activities 
against subtilisin. However, the function of the domain 1 of CrSPI (hereafter referred to 
as CrSPI-1-D1) is not yet characterized (Jiang et al., 2009).  Analysis of the CrSPI-1-D1 
sequence shows that it is significantly homologous to that of rhodniin-D1 from Rhodnius 
prolixus, which is a thrombin inhibitor (van de Locht et al., 1995). A number of 
endogenous thrombin inhibitors are available, and the most potent one is hirudin from the 
medicinal leech, Hirudo medicinalis (Rydel et al., 1991).  
 
In spite of several studies on serine protease inhibitors, CrSPIs are relatively new 
and potent (Jiang et al., 2009). There are several unexplored potentials and unanswered 
questions about CrSPIs, for example, what is the structural homology of the CrSPI 
domains, among themselves and other SPIs? What is the variance of target specificity and 
inhibition? In order to address these questions we have undertaken the structural and 
functional studies on CrSPI-1-D1. 
 In this chapter, we report the crystal structure of CrSPI-1-D1 refined up to 2.0Å 
resolution. Despite the close structural homology of CrSPI-1-D1 to rhodniin-D1, the 
native CrSPI-1-D1 does not inhibit thrombin. This motivated us to modify the selectivity 
of the CrSPI-1-D1 to specifically target thrombin. We show that sequential mutations in 
the RSL region of CrSPI-1-D1 generated a potent and specific thrombin inhibitor. The 
 82 
 
full length CrSPI-1 with this modified role of CrSPI-1-D1 as a thrombin modulator, 
might play a central role in regulating not only hemostasis but also inflammation, and 
may provide a close link between these processes and how they might co-evolve in the 
biological system. Furthermore, the possibilities to further develop this D1 mutant into a 
shorter yet active anti-thrombin holds potentials for biomedical applications as a 
coagulation modulator(Drag and Salvesen, 2010; Gurm and Bhatt, 2005; Markwardt, 
2002; Pfau, 2003; Steinmetzer et al., 2001; Turk, 2006a; Vacca, 2000; Weitz and 
Crowther, 2002).  
 
4.2  EXPERIMENTAL PROCEDURES 
4.2.1 Plasmid and strain construction 
  The CrSPI-1-D1 (encoding Cys1-Glu40) was PCR amplified using forward 
CTACTGGATCCTGTCCTCAT and reverse GCAGAGTTCGAATTCCTAGCAAGT 
TTC CCA primers that were designed to introduce a Bam H1 site to the 5` end and an 
Eco R1 site to the 3` end. Such PCR fragments were then digested with Bam H1 and Eco 
R1, and ligated into pET-M vector, which were previously linearized by compatible 
restriction enzymes, and transformed into Escherichia coli, BL 21. 
 
4.2.2 Expression and Purification 
 Optimal expression of the CrSPI-1-D1 was conducted by induction with 0.5mM 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) of 1 liter culture at 25 ºC. The cells were 
then disrupted by French Press and the supernatant were collected after centrifuging at 
10,000x g for 1 h at 4 ºC. His-tagged CrSPI-1-D1 proteins were purified in two steps 
using Ni-NTA (Qiagen) affinity chromatography followed by a Superdex 75 gel filtration 
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column on the Akta Express (GE Healthcare). The buffer was exchanged to a solution 
containing 20 mM Tris (pH-8.5), 150 mM NaCl, 5 mM dithiothreitol and finally 
concentrated up to 10 mg/ml. 
 
4.2.3 Crystallization and structure determination 
  Initial crystallization conditions were screened at 25 
o
C in the hanging drop vapor 
diffusion technique using Hampton Research crystallization screens and JB 
crystallization screens (Jena Biosciences) with drops containing equal volumes (1 μl) of 
reservoir and protein solution of 10 mg/ml against 0.5 ml of reservoir. Small rod-shaped 
crystals were formed within 2–3 days. Further optimization by equilibrating 1 µl CrSPI-
1-D1 protein solution of 15 mg/ml and 1 µl reservoir solution (0.4 M mono ammonium 
dihydrogen sulphate, 0.1 M Tris-HCl pH 8.5) using hanging drop vapor diffusion 
technique at 20 ºC led to best diffraction-quality crystals. The crystals diffracted up to 




 Crystals were cryo-protected in the reservoir solution supplemented with 25–30% 
glycerol, and flash cooled at 100 K. The diffraction data were obtained using a CCD 
detector (Platinum 135) mounted on a Bruker Microstar Ultra rotating anode generator 
(Bruker AXS, Madison, WI). All datasets were processed with HKL2000(Otwinowski 
and Minor, 1997). The structures were solved by molecular replacement with 
PHASER(McCoy et al., 2007). Subsequently the models were manually built by using 
COOT (Emsley and Cowtan, 2004), followed by refinement using CNS(Brunger et al., 




4.2.4 Site-directed mutagenesis 
 Based on the rhodniin-thrombin complex structure (PDB code 1tbq), residues 
Thr4, Tyr5, Lys6 and Pro7 of CrSPI-1-D1 were mutated to Ala, Leu, His and Arg 
respectively, the corresponding residues 8-11 of rhodniin that are crucial for interaction 
with thrombin (Table 4.2). We used inverse PCR based mutagenesis (Ochman et al., 
1988) to generate all mutants. In total, we generated 15 mutants (single to tetra). All 
mutant inhibitor proteins were expressed E. coli (BL21DE3) using optimized expression 
conditions and purified by His-tag based affinity and size exclusion column 
chromatography. The gel filtration purified CrSPI1-D1 was further purified by reverse 
phase chromatography through an analytical Jupiter C18 column on a Smart workstation 
(GE Healthcare) using a gradient (15-40% over 60 min) of buffer B (80% acetonitrile in 
0.1% TFA). The molecular masses of the RP-HPLC purified mutants were determined by 
ESI-MS on a Perkin-Elmer Sciex API III triple-stage quadrupole instrument equipped 
with an ionspray interface. 
 
4.2.5 CD spectroscopy 
  Far-UV CD spectra (260–190 nm) of CrSPI-1-D1 dissolved in 20 mM Tris-HCl 
buffer (pH 7.4) at a 30 μM protein concentration were collected using a Jasco J-810 
spectropolarimeter (Easton, MD). All measurements were carried out at room 
temperature using 0.1-cm path length cuvettes with a scan speed of 50 nm/min, a 




4.2.6 Stability verification of CrSPI-1-D1 mutants against serine proteases 
  20 μL of 1mg/ml CrSPI-1-D1 mutants were incubated with fixed quantity 1 μL 
of 1mg/ml of different serine proteases such as thrombin, trypsin, chymotrypsin, elastase 
and subtilisin at 37 ºC for 30 min. Reaction was stopped by heating the sample with 5X 
SDS loading dye at 100 ºC. One-dimensional (1-D) SDS PAGE was carried out 
following a standard protocol. 
 
4.2.7 Inhibition of Thrombin Amidolytic Activity 
  The buffer used in all functional assays was 20 mM Tris-HCl, pH 7.4. For all 
thrombin amidolytic activity assay, we used S2238 (H-D-Phenylalanyl-L-pipecolyl-
Larginine-p-nitroaniline dihydrochloride), which is a chromogenic substrate for thrombin 
from Chromogenix (Milano, Italy). To measure the inhibition activity of different CrSPI-
1-D1 proteins on thrombin activity, we performed all reactions in 96-wells microtiter 
plates. For each inhibition assay, 50 µl of 4.5 nM α-human thrombin was pre-incubated 
for 30 min at 37 ºC with increasing amounts (10 to 70 nM) 50 µl of CrSPI-1-D1 in a total 
reaction volume of 200 µl, prior to adding 100 µl of S2238. The rate of formation of 
colored product, p-nitroaniline, was read using an enzyme-linked immunosorbent assay 
plate reader at 405 nm for 10 min. Appropriate negative controls without the thrombin 
was assayed simultaneously. Percentage inhibition was calculated by taking the rate of 
increase in absorbance in the absence of inhibitor as 0%. A decrease in absorbance 
indicated the inhibitory effect of CrSPI-1-D1 on thrombin activity.  
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4.2.8 Isothermal Titration Calorimetry (ITC) 
 The ITC experiments were carried out using VP-ITC calorimeter (Microcal, LLC) 
at 20 °C using 300 μM of the protein in the sample cell and 40 μM of α-human thrombin 
in the injector. All samples were thoroughly degassed and then centrifuged to get rid of 
precipitates. Volumes of 10 µl per injection were used for the different experiments. For 
every experiment, the heat of dilution for each ligand was measured and subtracted from 
the calorimetric titration experimental 30 runs for the protein. Consecutive injections 
were separated by at least 4 min to allow the peak to return to the baseline. The ITC data 
was analyzed using a single site fitting model using Origin 7.0 (OriginLab Corp.) 
software. 
 
4.3  RESULTS 
4.3.1 Overall structure 
  The structure of CrSPI-1-D1 was solved by molecular replacement method and 
refined to a final R-factor of 0.21 (Rfree=0.25) at 2.0Å resolution. The model has been 
refined with good stereo chemical parameters (Table 4.1). There are two CrSPI-1-D1 
monomers in the asymmetric unit. The structure of CrSPI-1-D1 mostly consists of loops 
with a two-strand (Val8-Gly10 and Gly13-Tyr16) β-sheet and a two-turn α-helix. In 
addition, a single turn α-helix (Trp33-Cys36) is present at the C-terminal. A disulphide 
bond is located between Cys1 and Cys20 to help maintain the rigidity of the RSL. The 
carboxyl terminus is linked to the N-terminal through a second disulphide bridge, Cys9-





Figure IV.1: Structure of CrSPI-1-D1.(A) Ribbon diagram of the CrSPI-
1-D1. (B) 90˚ rotated side view. α-Helix, β-strands and random coils are 
depicted in red, yellow and green, respectively. The disulfide bridges are 
shown in green. The secondary structures, N- and C-termini, are labeled. 
This figure and the following figures of this manuscript were prepared 
using the program PyMoL(DeLano and Lam, 2005) .  
 
 
4.3.2 Structural comparison 
  A search for topologically similar domains within the PDB database using the 
DALI program (Holm and Sander, 1998) revealed that the structural features of CrSPI-1-
D1 resemble the typical non-classical Kazal type inhibitor (Hemmi et al., 2005). The 
highest structural similarity is observed between hirudin, the leech-
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derived tryptase inhibitor from H. medicinalis and CrSPI-1-D1, yielding an rmsd of 1.9 Å 
for 36 Cα atoms (pdb code 1ldt). This is followed by a thrombin protease inhibitor, 
rhodniin domain 1 (rhodniin-D1) from Rhodnius prolixus, which yielded an rmsd of 2.0 
Å for 36 Cα atoms (pdb code 1tbq). 
 In addition to the structural homology, the CrSPI-1-D1 and rhodniin-D1 display 
42% sequence identity while only 35% sequence identity was observed with hirudin. The 
structure-based sequence alignment revealed that most of the structurally invariant 
residues are located at the carboxy terminus, including the RSL, β1, β2 and α1 of CrSPI-
1-D1 (Figure 4.2). These observed features provided a clue that CrSPI-1-D1 might 
specifically target thrombin after modifications of a few residues in the RSL, and this 






Table IV.1: Data collection and refinement statistics of CrSPI-1-D1 
 
Experiment 
Cell parameters (Å, °)   a= 25.5, b= 37.2, c= 36.5, α=90, β= 99.8, γ=90 
Space group      P21       
Data collection 
a
       
Resolution range (Å)        50.0-2.0 (2.07-2.00)      
Observed Reflections   28,930      
Unique Reflections   4,535       
Redundancy        6.4 (3.2)           
Completeness (%)       97.3 (80.7)       
Overall (I/σI)        31.3       
Rsym
b
          0.046 (0.061)      
Refinement 
Resolution range (Å)      20.0-2.0           





 (%)       21.47/25.56         
RMSD bond lengths (Å)      0.009          
RMSD bond angles (°)      1.660          
Average B-factors (Å
2
)      18.046 
Main chain (# atoms)   16.045 (312) 
Side chain (# atoms)   18.394 (264) 
Water (# atoms)   27.559 (56)           
Ramachandran Plot 
Most favored region (%)  93.4  
Additional allowed regions (%) 4.9           
Generously allowed regions (%) 1.6           
Disallowed regions (%)  0.0           
a. Numbers in parentheses refer to the highest resolution shell. 
b. Rsym = Σ|Ii – <Ii>| / Σ| Ii| 
c. Rfactor = Σ||Fobs| − |Fcalc||/Σ|Fobs| 





Figure IV.2: Comparison of CrSPI-1-D1 with rhodniin-D1. (A) Stereo Cα 
superposition of CrSPI-1-D1 (red) and rhodniin-D1 (cyan). The RMSD 
between CrSPI-1-D1 and rhodniin-D1 is 2.0 Å for 36 Cα atoms. (B) 
Structure based sequence alignment between CriSPI-1-D1 and rhodniin-
D1. This alignment was performed using the program COOT (Emsley and 
Cowtan, 2004). The secondary structural elements for CrSPI-1-D1 and 
rhodniin-D1 are shown at the top and the bottom, respectively. The 
conserved residues are highlighted in red boxes outlined in blue. This 





4.3.3 The reactive-site loop 
 Although the sequence of the reactive-site loop (RSL) is different in several 
families of serine protease inhibitors, the conformation of the RSL is similar (Jiang et al., 
2009; van de Locht et al., 1995). Like other Kazal-type inhibitors, the disulfide bonds 
formed by cysteine residues at the P3 and P5’ positions (Cys1 and Cys9 in CrSPI-1-D1) 
hold the RSL in a relatively rigid conformation. Besides, there are several internal 
hydrogen bonds (<3.2 Å) which help maintain the rigidity of the RSL in the CrSPI-1-D1. 
Figure 3c shows selected hydrogen bonding contacts between RSL and CrSPI-1-D1. 
Notably, strong intra-molecular H-bonds (< 3.0 Å) were observed between the carbonyl 
oxygen of Pro2 (P2 position) and amide nitrogen of Thr4 (P1’ position); Asn18 and 
Phe21, ND2 of Asn18 interacts with the main chain carbonyl atoms of Pro2 and Thr4 at 
the P2 and P1’ positions of the RSL, respectively (Table 4.2).   
 92 
 
Table IV.2: Interaction involved for rigidity of reactive site loop of CrSPI-1-D1 




O (Pro2,P1΄ position)-ND2 (Asn18) 2.94 
O (Thr4,P2΄ position)-ND2 (Asn18) 2.85 
OD1 (Asn18)- N(Phe21) 2.86 
O(Asn18)-N(Phe21) 3.14 




O (Pro9,P1΄ position)-ND2 (Asn25) 3.50 
O (Ala 11,P2 position )-ND2 (Asn25) 2.80 
OD1 (Asn18)- N(Thr28) 3.17 
O(Asn18)-N(Thr28) 3.13 




O (Thr 17,P1΄ position)-ND2 (Asn33) 2.84 
O (Glu 19,P2 position )-ND2 (Asn33) 3.00 
OD1 (Asn33)- N(Asn 36) 3.00 
O(Asn18)-N(Asn 36) 3.20 
O (Thr17,P1΄ position)-N (Glu19,P2 position) 3.75 
 
 Similar interactions were observed in rhodniin-D1 and other protease inhibitors 
such as the turkey ovomucoid third domain, OMTKY3, although there are different 
amino acids in those positions (Maynes et al., 2005). In addition to the S-S bonds, these 
hydrogen bonds are essential to maintain the rigidity of the RSL during the inhibition of 
the cognate enzyme. Although a similar rigid conformation is found in these inhibitors, 
they recognize the substrates differently. This clearly shows that in addition to the rigid 
conformation, the sequence of the RSL dictates the selectivity towards a particular 
protease. Thus, we have mutated the RSL side chains of CrSPI-1-D1 to specifically target 




Figure IV.3: The reactive-site loop (RSL). (A) The site-directed mutation 
on CrSPI-1-D1. A transparent surface representation of the CrSPI-1-D1 is 
shown with all mutated residues in stick representation in magenta. (B) 
Stereo view of the electron density map. Simulated annealing Fo-Fc omit 
map of the N-terminal region of CrSPI-1-D1 showing the key residues in 
reactive-site loop. All residues shown in this figure as well as all atoms 
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within 2 Å of these residues were omitted prior to refinement and map 
calculation. The map was contoured at a level of 2.0 σ. (C) A close view 
shows the interactions aid in maintaining the rigidity of the RSL. Cα of the 
CrSPI-1-D1 is shown in red. The disulfide bonds are shown in yellow, 
stick line while the hydrogen bonds are shown in black, dotted lines. 
 
4.3.4 Mutations to change the specificity 
  Following the structure determination of CrSPI-1-D1, the next main objective 
was to elucidate the inhibitory efficiency of this domain. Our previous studies showed 
that full length as well as domain 2 of CrSPI-1 is a specific inhibitor of subtilisin, 
however the specificity of domain-1 is not yet established (Jiang et al., 2009). An 
analysis of P3 to P4` residues of the RSLs of various substrates like binding serine 
protease inhibitors such as for subtilisin, thrombin, trypsin, chymotrypsin and furin was 
performed to identify the minimum side chains of CrSPI-1-D1 to be mutated to alter the 
selectivity (Table 4.3). The closest similarities were observed with RSLs of rhodniin-
domain-1. P3, P2 and P1 of CrSPI-1-D1 and rhodniin-D1 are similar, but P1`, P2`, P3` 
and P4` were different. Complex crystal structure of rhodniin and thrombin showed that 
the N terminal domain of rhodniin interacts with the active-site cleft region of thrombin 
(PDB 1tbq). In addition to the interactions of Pro9, His10 and Alall, the side chain of 
Leu12 occupies the S2' site of thrombin. His13 mediates a hydrogen bond and stacks with 
aromatic residues in S3'. Arg14 at P4' allows charge compensation of Glu39 from 
thrombin. The clustering of the positively charged inhibitor residues at P3' and P4' might 
be particularly beneficial for thrombin binding (Lombardi et al., 1999). Based on these 
observations we have introduced mutations in the RSL region of CrSPI-1-D1, which was 
previously of uncharacterized function, to specifically target thrombin.  
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Table IV.3: Reactive site loop regions from P3 to P4’ position of selected serine protease inhibitors 
























LDTI ( Leech Derived 
Tryptase Inhibitor ) 









Tomato inhibitor II 
dommain-2 









Spn4A (Furin inhibitor 
from Drosophila) 





( Furin Inhibitor) 








Figure IV.4.5: Modeling complex of CrSPI-1-D1 with thrombin. (A) 
Complex structure of rhodniin with thrombin (pdb code 1tbq). Rhodniin 
and thrombin are shown in cyan and yellow, respectively. CrSPI-1-D1 
(red) was superimposed on rhodniin-D1. (B) Thrombin is shown as 
surface representation in this model complex. (C) Close up view of the 
RSL of CrSPI-1-D1 in the active site of thrombin.   
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 Our approach was to mimic the P1`, P2`, P3` and P4` residues (Thr4, Tyr5, Lys6 
and Pro7) of CrSPI-1-D1 to rhodniin-D1 (Ala11, Leu12, His13 and Arg14); to 
sequentially mutate and evaluate the implication of these four residues towards thrombin 
inhibition.  In addition to the tetra mutant, we have tried all possible single, double and 
triple mutants. A total of 15 mutants (Table 4.4) have been generated and their thrombin 
inhibition was studied. All the mutants were expressed in bacteria and purified as wild 
type CrSPI-1-D1 (Fig. 4.5) .The CD spectrum was recorded on all 15 mutants of CrSPI-
1-D1, which indicated that these mutants share the same α/β structure as the wild type 
CrSPI-1-D1 (Fig. 4.6). Furthermore, the ESI-MS spectrum showed their expected 
molecular mass (Fig.4.9).  
 
Figure IV.5: Reverse Phase-HPLC profile of CrSPI-1-D1.Gel filtration 
purified CrSPI-1-D1 was loaded onto an analytical Jupiter C18 analytical 
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column on SMART Workstation (GE-healthcare) using a gradient (15 - 
40% over 60 min) of buffer B (80% ACN in 0.1% TFA. Figure shows the 
elution of protein monitored at 215 nm.  The peak (indicated with the 
arrow) contains a single homogenous CrSPI-1-D1 taken for kinetics 
studies. 
 
We have verified the stability of the CrSPI-1-D1 mutants as a possible inhibitor 
against different serine proteases such as thrombin, trypsin, chymotrypsin, elastase and 
subtilisin. Notably only the tetra mutant is stable against thrombin, whereas other serine 
proteases degrade the modified CrSPI-1-D1, which seemed to act more as substrate rather 
than an inhibitor (Fig. 4.7). It suggests that CrSPI-1-D1 mutant is thrombin specific. In 
the following section we describe the inhibition studies of CrSPI-1-D1 mutants with 
thrombin. 
 
Figure IV.6: CD spectroscopy profile of reverse phase HPLC purified 
CrSPI-1-D1.Far-UV CD spectra (260–190 nm) of CrSPI-1-D1 dissolved 
in 20 mM Tris-HCl buffer  (pH 7.4) at a 30 μM protein concentration were 
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collected using a Jasco J-810 spectropolarimeter (Easton, MD). All 
measurements were carried out at room temperature using 0.1-cm path 
length cuvettes with a scan speed of 50 nm/min, a resolution of 0.2 nm, 
and a bandwidth of 2 nm. The CD spectrum of the tetra mutant of CrSPI-
1-D1 indicated that it assumed an α/β structure. 
 
Table IV.4: IC50 and dissociation constant (Kd) for the inhibition of 
thrombin by various variants of CrSPI-1-D1 
S.No. Mutants IC50 Kd  
1 T4A ND ND 
2 Y5K ND ND 
3 K6H ND ND 
4 P7R ND ND 
5 T4A,Y5K  ND ND 
6 T4A,K6H  ND ND 
7 T4A,P7R  ND ND 
8 Y5K,K6H ND ND 
9 Y5K,P7R  ND ND 
10 K6H,P7R  ND ND 
11 T4A,Y5K,K6H  ND ND 
12 T4A,Y5K,P7R  ND ND 
13 T4A,K6H,P7R  ND ND 
14 Y5K,K6H,P7R ND ND 
15 T4A,Y5K,K6H,P7R  26.3nM 4μM 




Figure IV.7: The specificity of CrSPI-1-D1 tetra mutant for thrombin 
ascertained by comparison with other proteases.SDS-PAGE analysis for 
the interaction of CrSPI-1-D1 wild type and tetra mutant with different 
proteases. A) Lane 1 protein marker ; Lane 2 CrSPI-1-D1 alone and Lane 
3-7 CrSPI-1-D1 wild type incubated with α-human thrombin, 
chymotrypsin, trypsin, elastase and subtilisin, respectively, for 37 ºC for 
30 min. B) Lane 1 protein marker; Lane 2 T4A,Y5K,K6H,P7R CrSPI-1-
D1 alone and Lane 3-7 T4A,Y5K,K6H,P7R CrSPI-1-D1 incubated with α-
human thrombin, chymotrypsin, trypsin ,elastase and subtilisin, 
respectively, for 37 ºC for 30 min.  
 
4.3.5 Thrombin inhibition assay 
  Previously it has been shown that hirudin has very high inhibitory activity against 
the α-human thrombin(Markwardt, 1994). We chose to study the properties of these 
CrSPI-1-D1 variants under a similar condition as hirudin:α-human thrombin complex. 
Out of all 15 CrSPI-1-D1 mutants, only tetra mutant (T4A, Y5K, K6H, P7R) showed the 




 Fig. 4.10 shows the typical dose-response curves. Wild type CrSPI-1-D1 showed 
no inhibition, whereas the tetra mutant exhibited strong inhibition against thrombin. The 
dose response plot of the fractional velocity as a function of different concentrations of 
tetra mutant CrSPI-1-D1 showed that 26.3 nM of tetra mutant CrSPI-1-D1 was sufficient 
to inhibit 50% of 4.5 nM thrombin (Fig. 4.8). Since the IC50 value of 26.3 nM is within a 
factor of 10 of the concentration of thrombin and CrSPI-1-D1, it is ascertained that the 
mode of inhibition follows the typical kazal domain’s mode of inhibition. Following the 
inhibition studies, we verified the binding affinities of these mutants of CrSPI-1-D1 with 
α-human thrombin using ITC experiments. 
 
 
Figure IV.8: Determination of IC50 values based on dose response plots 
of fractional velocity as a function of different tetra mutant CrSPI-1-D1 




and formation of colored product, p-nitroaniline, by 4.5 nM thrombin in a 
total reaction volume of 200μL. Vo and Vi are the initial velocities in the 
absence and presence of tetra mutant CrSPI-1-D1, respectively and were 
calculated from Beer-Lambert’s Law. Hence, the tetra mutant CrSPI-1-D1 
concentration predicted to block 50% of the activity of a fixed 
concentration of thrombin was obtained on a graphical plot of Vi/Vo 
versus inhibitor concentration. 
 
 
Figure IV.9: ESI/MS profile of reverse phase HPLC purified CrSPI-1-D1. 
The spectrum shows a series of multiply charged ions, corresponding to 
the correct molecular mass of 6644± 0.22 Da. The purity and mass of all 
mutant proteins of CrSPI-1-d1 were determined by electro spray 
ionization mass spectrometry using an API 300 liquid chromatography 






Figure IV.10: Concentration dependent Inhibition of α-human thrombin by CrSPI1-D1 and its mutant: (A) wild type 
CrSPI-1-D1 and (B) T4A,Y5K,K6H,P7R CrSPI-1-D1. Residual protease activity was measured as OD405 based on 
hydrolysis of 0.1 mM S2238 (H-D-Phenylalanyl-L-pipecolyl-Larginine-p-nitroaniline dihydrochloride) and formation 
of colored product, p-nitroaniline, by 4.5 nM thrombin in a total reaction volume of 200 μL. The concentration of wild 
type CrSPI-1-D1 and T4A, Y5K, K6H, P7R CrSPI-1-D1 are indicated next to the curve. 
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4.3.6 Isothermal Titration Calorimetry (ITC) studies 
 To verify the interactions between the CrSPI-1-D1 and thrombin, we have 
performed ITC experiments with wild type CrSPI-1-D1 and selected mutants against 
thrombin. The wild type CrSPI-1-D1 and the mutants which lacked thrombin inhibition 
did not show any binding with thrombin. Consistent with the results of thrombin 
inhibition assays, only the tetra mutant showed interactions with α-human thrombin with 
dissociation constant (Kd) of 4 μM (Fig. 4.11). The model used for the ITC analysis is a 
single site binding model assuming a stoichiometric ratio of 1:1 (CrSPI-1-D1: thrombin). 
 
Figure IV.11: Isothermal Titration Calorimetry analysis. (A) α-human 
thrombin – wild type CrSPI-1-D1 titration. (B) α-human thrombin - T4A, 
Y5K, K6H, P7R CrSPI-1-D1 titration. The upper panels show the 
injection profile after baseline correction and the bottom panel shows the 
integration (heat release) for each injection. 
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4.3.7 IC50 and affinity 
For enzyme inhibitors, the dissociation constant Kd is usually termed the 
inhibition constant Ki . It is important to be aware that data from enzyme inhibition is 
often reported not as Ki(or, equivalently, Kd), but instead as the IC50, the concentration 
of ligand that reduces enzyme activity by 50%.  The difference between IC50 and Ki 
results from the fact, in an enzymatic binding assay of a competitive enzyme inhibitor, 
the inhibitor is not the only molecule trying to bind the enzyme’s active site.  It is 
competing with the substrate, so the concentration of ligand needed to reduce the 
enzymatic activity by 50% depends on the concentration of substrate and how tightly it 
binds the enzyme. IC50 is not a direct indicator of affinity although the two can be related 
at least for competitive agonists and antagonists by the Cheng-Prusoff equation.
[4]
 In 
general, then, the IC50 is expected to be greater than Ki (Cheng-Prusoff equation). IC50 
is not a direct indicator of affinity, nor is Kd/Ki a direct indicator of inhibition.  However, 
the two can be related using the Cheng-Prusoff equation: 
 
 
where Ki is the binding affinity of the inhibitor, IC50 is the functional strength of 
the inhibitor, [S] is substrate concentration and Km is the concentration of substrate at 
which enzyme activity is at half maximal (but is frequently confused with substrate 
affinity for the enzyme, which it is not). Whereas the IC50 value for a compound may 
vary between experiments depending on experimental conditions, the Ki is an absolute 
value. 
Binding of a protein with a drug-like molecule often leads to a small amount of 
heating or cooling of the solution; i.e., the reaction can be exothermic or endothermic.  
Isothermal titration calorimetry(ITC) measures binding through detection of these 
changes. An ITC assay tends to require a larger quantity of sample (protein and ligand) 
than an enzyme inhibition assay, since it does not have the same property of 
amplification (see above).  However, ITC has the advantage of not requiring the 
development of a specialized substrate whose reaction can be detected; the natural heat 
release of the binding reaction is that that is needed. Note, however, that some binding 
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reactions neither take up nor release much heat, and these are not so easily monitored by 
ITC.   
It is also worth reiterating that there are additional sources of variation among 
binding measurements for a given protein and ligand. These include the choice of enzyme 
substrate in enzyme IC50 assays, the pH, temperature, and ionic strength, and potentially 




 The Carcinoscorpius rotundicauda is an ancient invertebrate that has survived for 
several hundred million years, and thus termed a ‘living fossil’. Being able to efficiently 
defend against the multitude of pathogens that thrive in its habitat and survive in this 
harsh environment, suggests that it possesses a very powerful innate immune defense 
system. Serine Protease Inhibitors (SPIs) serve important roles in immunity by 
inactivating and clearing the proteases from the invading pathogens, which use them as 
virulence factors. How did multidomain SPIs arise? The SPI domains are ‘evolutionarily 
mobile’ (Ikeo et al., 1995). In the process of evolution, domains from different families of 
SPIs could have been shuffled and fused in a single inhibitor, resulting in a multidomain 
inhibitor. 
The evolutionary mechanisms of SPIs serve to increase their variety and expand 
their functions, thus helping to meet the demands of the repertoire of endogenous and 
exogenous SPs an organism encounters. Thus, knowing the structure of an inhibitor 
usually provides insights into its inhibitory functions. More importantly, the structural 
changes of a protease inhibitor in complex with its target protease can provide useful 
information on the interaction between the two proteins, thus allowing the development 
of analogs of that inhibitor with increased affinity towards the protease to achieve greater 
inhibition capacity. This motivated us to modify the selectivity of CrSPI-1-D1 to 
specifically target thrombin and here we show that selected mutation in the RSL region of 




 We have determined the crystal structure of CrSPI-1-D1 refined up to 2.0Å 
resolution, from the horseshoe crab, C. rotundicauda. Although the native CrSPI-1-D1 
itself is highly homologous to the thrombin inhibitor, rhodniin domain 1 (rhodniin-D1) 
from R. prolixus, native CrSPI-1-D1 does not inhibit thrombin. Therefore, our directed 
mutation of the RSL represents a structure-based drug design approach in the conversion 
of an uncharacterized CrSPI-1-D1 into a potent thrombin inhibitor with an IC50 of 26.3 
nM. Furthermore, our studies revealed that besides the rigid conformation of the RSL, the 
sequence is most important to dictate the specificity of the inhibitor. This study adds an 
important implication to modifying a multidomain inhibitor protein. The CrSPI-1 has 
been shown to target two molecules of proteases. The modified domain D1 targets 
thrombin, whereas the wild type domain D2 targets subtilisin (Jiang et al., 2009). 
Moreover, this may lead to further development of the D1 mutant into a shorter active 




CHAPTER-V: CONCLUSION AND FUTURE DIRECTION 
 
5.1  CONCLUSIONS 
5.1.1 Cr-TRP16 and its role in NF-kB signaling pathways 
 The first part of this thesis, reports the NMR structure of the reduced form of 
wild-type Cr-TRP16, along with functional studies. We have demonstrated the role of the 
C15 residue of in the dimer formation of Cr-TRP16 by site directed mutagenesis and 
biophysical methods such as Analytical Ultracentrifugation (AUC), NMR and gel-
filtration. Moreover the ex-vivo study in HeLa cells for the wild type and C15S Cr-
TRP16 were found consistent with the biophysical results and reveals the role of the 
additional N-terminal Cys residue in the regulation of NF-kB activity under oxidative 
stress. These studies shed light in understanding the interactions of Trxs and Trx-like 
proteins with other metabolic pathways and their physiological relevance and will 
eventually lead to developing promising therapeutic strategies to modulate the action of 
Trx and NF-B. 
 
5.1.2 Modifying the substrate specificity of a Cr inhibitor to target thrombin 
 The second part of this thesis reports the crystal structure of CrSPI-1-D1 from C. 
rotundicauda, refined at 2.0Å resolution. Although the structure of the native CrSPI-1-D1 
itself is highly homologous to the thrombin inhibitor, rhodniin domain 1 (rhodniin-D1) 
from R. prolixus, native CrSPI-1-D1 does not inhibit thrombin. Therefore, the site 
directed mutations on the Reactive Site Loop (RSL) represents a structure-based drug 
design approach to transform uncharacterized CrSPI-1-D1 into a potent and specific 
inhibitor of thrombin with an IC50 of 26.3 nM. Moreover results presented in this part of 
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thesis reveal that in addition to the rigid conformation of the RSL, the sequence is most 
important to dictate the specificity of the inhibitor. This study adds an important 
implication to modify any multi-domain inhibitor protein to target any specific substrate. 
 
5.2  FUTURE DIRECTION 
 Based on the experiments and results reported in this thesis continuation of these 
studies is proposed in the following sections. In vertebrates, there are two families of 
TRXs with high homology to the 16 kDa Cr-TRP16; one is 16 kDa and another one is 24 
kDa (TXNL6). However only invertebrates possess the 16 kDa TRXs and bacteria are 
devoid of these homologues. This observation suggests that the 16 kDa TRXs have 
evolutionarily diverged from the 12 kDa TRXs at an early stage and the 16 kDa TRXs 
probably underwent gene duplication and divergence in the vertebrates and gave rise to 
the 24 kDa TXNL-6 (Zhang, 2003).  
 
5.2.1 Structural insights into the mechanism of TXNL-6 / NF-κB complex in 
protection of human photoreceptor cells from photo oxidative damage 
  Interestingly, unlike the invariable WCPPC catalytic motif in Cr-TRP16, the 
active sites of the 24 kDa human TXNL-6 have undergone marked changes. Therefore, it 
will be interesting to investigate if human TXNL-6 still conserve and exhibit the basic 
structural and functional features like the Cr-TRP16 counterparts. Simultaneously, it 
would be pertinent to explore the structural and functional similarities /differences 




5.2.2 Development of smaller and less immunogenic potent thrombin inhibitor  
 Given the central role of thromboembolism in cardiovascular disease, inhibition 
of thrombosis has become a key therapeutic strategy. Our structure directed protein 
engineering of the reactive site loop (RSL) leads to the conversion of an uncharacterized 
CrSPI-1-D1 into one of the smallest (40 residues) potent thrombin inhibitor. Moreover, 
this may lead to further development of the D1 variant into a shorter (10-12 residues) and 
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